Identification

Name
L-Tryptophan
Accession Number
DB00150  (NUTR00058, EXPT02064)
Type
Small Molecule
Groups
Approved, Nutraceutical, Withdrawn
Description

An essential amino acid that is necessary for normal growth in infants and for nitrogen balance in adults. It is a precursor of indole alkaloids in plants. It is a precursor of serotonin (hence its use as an antidepressant and sleep aid). It can be a precursor to niacin, albeit inefficiently, in mammals.

Structure
Thumb
Synonyms
  • (2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
  • (S)-alpha-Amino-beta-(3-indolyl)-propionic acid
  • (S)-Tryptophan
  • (S)-α-amino-1H-indole-3-propanoic acid
  • L-(-)-Tryptophan
  • L-(−)-tryptophan
  • L-β-3-indolylalanine
  • Trp
  • Tryptophan
  • W
External IDs
NSC-13119
Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Tryptan Cap 500mgCapsule500 mgOralValeant Canada Lp Valeant Canada S.E.C.1986-12-31Not applicableCanada
Tryptan Tab 1000mgTablet1 gOralValeant Canada Lp Valeant Canada S.E.C.1986-12-31Not applicableCanada
Tryptan Tab 250mgTablet250 mgOralValeant Canada Lp Valeant Canada S.E.C.1999-01-06Not applicableCanada
Tryptan Tab 500mgTablet500 mgOralValeant Canada Lp Valeant Canada S.E.C.1994-12-31Not applicableCanada
Tryptan Tab 750mgTablet750 mgOralValeant Canada Lp Valeant Canada S.E.C.1999-01-06Not applicableCanada
Generic Prescription Products
NameDosageStrengthRouteLabellerMarketing StartMarketing End
Apo-tryptophanTablet750 mgOralApotex Corporation2017-02-06Not applicableCanada
Apo-tryptophanTablet500 mgOralApotex Corporation2003-12-09Not applicableCanada
Apo-tryptophanCapsule500 mgOralApotex Corporation2003-12-09Not applicableCanada
Apo-tryptophanTablet250 mgOralApotex CorporationNot applicableNot applicableCanada
Apo-tryptophanTablet1 gOralApotex Corporation2003-12-09Not applicableCanada
Dom-tryptophanTablet1 gOralDominion PharmacalNot applicableNot applicableCanada
PHL-tryptophanTablet500 mgOralPharmel Inc2005-03-232016-10-25Canada
PHL-tryptophanCapsule500 mgOralPharmel Inc2005-03-232016-10-25Canada
PHL-tryptophanTablet1 gOralPharmel Inc1998-02-172016-10-25Canada
PMS-tryptophanCapsule500 mgOralPharmascience Inc2003-02-14Not applicableCanada
Mixture Products
NameIngredientsDosageRouteLabellerMarketing StartMarketing End
2.5% Travasol Amino Acid Injection With Electrolytes In 10% DextroseL-Tryptophan (45 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + L-Alanine (520 mg) + L-Arginine (290 mg) + L-Isoleucine (150 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Proline (170 mg) + L-Threonine (105 mg) + L-Tyrosine (10 mg) + L-Valine (145 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Serine (125 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection With Electrolytes In 10% Dextrose ClinimixL-Tryptophan (45 mg) + Dextrose, unspecified form (10 g) + Dipotassium phosphate (130.5 mg) + Glycine (520 mg) + Histidine (110 mg) + L-Alanine (520 mg) + L-Arginine (260 mg) + L-Isoleucine (120 mg) + L-Leucine hydrochloride (155 mg) + L-Lysine hydrochloride (145 mg) + Phenylalanine hydrochloride (155 mg) + L-Proline (105 mg) + L-Threonine (105 mg) + L-Tyrosine (10 mg) + L-Valine (115 mg) + Magnesium chloride (25.5 mg) + Methionine (145 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312015-08-05Canada
2.5% Travasol Amino Acid Injection Without Electrolytes In 10% Dextrose QuickmixL-Tryptophan (45 mg) + Dextrose, unspecified form (10 g) + Glycine (520 mg) + Histidine (110 mg) + L-Alanine (520 mg) + L-Arginine (260 mg) + L-Isoleucine (120 mg) + L-Leucine hydrochloride (155 mg) + L-Lysine hydrochloride (195 mg) + Phenylalanine hydrochloride (155 mg) + L-Proline (105 mg) + L-Threonine (105 mg) + L-Tyrosine (10 mg) + L-Valine (115 mg) + Methionine (195 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
2.5%travasol Amino Acid InJ.W.eleC.W.25%dexL-Tryptophan (45 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (130.5 mg) + Glycine (260 mg) + Histidine (120 mg) + L-Alanine (520 mg) + L-Arginine (290 mg) + L-Isoleucine (150 mg) + L-Leucine (182.5 mg) + L-Lysine (145 mg) + L-Phenylalanine (140 mg) + L-Proline (170 mg) + L-Threonine (105 mg) + L-Tyrosine (10 mg) + L-Valine (145 mg) + Magnesium chloride (25.5 mg) + Methionine (100 mg) + Serine (125 mg) + Sodium Chloride (29.3 mg) + Sodium acetate (170 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travas. Amino Acid InJ.W.elecw.25%dexL-Tryptophan (49.5 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + L-Alanine (570 mg) + L-Arginine (316 mg) + L-Isoleucine (165 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Proline (187 mg) + L-Threonine (115.5 mg) + L-Tyrosine (11 mg) + L-Valine (159.5 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Serine (137.5 mg) + Sodium Chloride (112 mg) + Sodium acetate (215.5 mg)LiquidIntravenousClintec Nutrition Company1996-07-301998-08-13Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 25% Dextrose QuickmixL-Tryptophan (49.5 mg) + Dextrose, unspecified form (25 g) + Dipotassium phosphate (261 mg) + Glycine (570 mg) + Histidine (120.5 mg) + L-Alanine (570 mg) + L-Arginine (285 mg) + L-Isoleucine (131.5 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Proline (115 mg) + L-Threonine (115 mg) + L-Tyrosine (11 mg) + L-Valine (126 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Sodium Chloride (112 mg) + Sodium acetate (215.5 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1996-02-022007-08-02Canada
2.75% Travasol Amino Acid Injection With Electrolytes In 5% Dextrose QuickmixL-Tryptophan (49.5 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (215.5 mg) + Glycine (570 mg) + Histidine (120.5 mg) + L-Alanine (570 mg) + L-Arginine (285 mg) + L-Isoleucine (131.5 mg) + L-Leucine hydrochloride (170 mg) + L-Lysine hydrochloride (159 mg) + Phenylalanine hydrochloride (170 mg) + L-Proline (115 mg) + L-Threonine (115 mg) + L-Tyrosine (11 mg) + L-Valine (126 mg) + Magnesium chloride (51 mg) + Methionine (159 mg) + Sodium Chloride (112 mg) + Sodium acetate (256 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1993-12-312007-08-02Canada
2.75%travasol Amino Acid InJ.W.eleC.W.5%dex.L-Tryptophan (49.5 mg) + Dextrose, unspecified form (5 g) + Dipotassium phosphate (261 mg) + Glycine (283 mg) + Histidine (132 mg) + L-Alanine (570 mg) + L-Arginine (316 mg) + L-Isoleucine (165 mg) + L-Leucine (201 mg) + L-Lysine (159.5 mg) + L-Phenylalanine (154 mg) + L-Proline (187 mg) + L-Threonine (115.5 mg) + L-Tyrosine (11 mg) + L-Valine (159.5 mg) + Magnesium chloride (51 mg) + Methionine (110 mg) + Serine (137.5 mg) + Sodium Chloride (112 mg) + Sodium acetate (215 mg)LiquidIntravenousClintec Nutrition Company1996-12-311999-08-10Canada
20% ProsolL-Tryptophan (0.32 g) + D-Methionine (0.76 g) + Glutamic Acid (1.02 g) + Glycine (2.06 g) + Histidine (1.18 g) + L-Alanine (2.76 g) + L-Arginine (1.96 g) + L-Aspartic Acid (0.6 g) + L-Isoleucine (1.08 g) + L-Leucine (1.08 g) + L-Lysine (1.35 g) + L-Phenylalanine (1 g) + L-Proline (1.34 g) + L-Threonine (0.98 g) + L-Tyrosine (0.05 g) + L-Valine (1.44 g) + Methionine (0.76 g) + Serine (1.02 g)LiquidIntravenousBaxter Laboratories1996-10-09Not applicableCanada
4.25% Amino Acid Injection Without Electrolytes In 20% Dextrose QuickmixL-Tryptophan (76 mg) + Dextrose, unspecified form (20 g) + Glycine (880 mg) + Histidine (186 mg) + L-Alanine (880 mg) + L-Arginine (440 mg) + L-Isoleucine (203 mg) + L-Leucine hydrochloride (263 mg) + L-Lysine hydrochloride (246 mg) + Phenylalanine hydrochloride (263 mg) + L-Proline (178 mg) + L-Threonine (178 mg) + L-Tyrosine (17 mg) + L-Valine (195 mg) + Methionine (246 mg)SolutionIntravenousBaxter Corporation Clintec Nutrition Division1995-12-312007-08-02Canada
International/Other Brands
Alti-Tryptophan
Categories
UNII
8DUH1N11BX
CAS number
73-22-3
Weight
Average: 204.2252
Monoisotopic: 204.089877638
Chemical Formula
C11H12N2O2
InChI Key
QIVBCDIJIAJPQS-VIFPVBQESA-N
InChI
InChI=1S/C11H12N2O2/c12-9(11(14)15)5-7-6-13-10-4-2-1-3-8(7)10/h1-4,6,9,13H,5,12H2,(H,14,15)/t9-/m0/s1
IUPAC Name
(2S)-2-amino-3-(1H-indol-3-yl)propanoic acid
SMILES
N[C@@H](CC1=CNC2=CC=CC=C12)C(O)=O

Pharmacology

Indication

Tryptophan may be useful in increasing serotonin production, promoting healthy sleep, managing depression by enhancing mental and emotional well-being, managing pain tolerance, and managing weight.

Pharmacodynamics

Tryptophan is critical for the production of the body's proteins, enzymes and muscle tissue. It is also essential for the production of niacin, the synthesis of the neurotransmitter serotonin and melatonin. Tryptophan supplements can be used as natural relaxants to help relieve insomnia. Tryptophan can also reduce anxiety and depression and has been shown to reduce the intensity of migraine headaches. Other promising indications include the relief of chronic pain, reduction of impulsivity or mania and the treatment of obsessive or compulsive disorders. Tryptophan also appears to help the immune system and can reduce the risk of cardiac spasms. Tryptophan deficiencies may lead to coronary artery spasms. Tryptophan is used as an essential nutrient in infant formulas and intravenous feeding. Tryptophan is marketed as a prescription drug (Tryptan) for those who do not seem to respond well to conventional antidepressants. It may also be used to treat those afflicted with seasonal affective disorder (a winter-onset depression). Tryptopan serves as the precursor for the synthesis of serotonin (5-hydroxytryptamine, 5-HT) and melatonin (N-acetyl-5-methoxytryptamine).

Mechanism of action

A number of important side reactions occur during the catabolism of tryptophan on the pathway to acetoacetate. The first enzyme of the catabolic pathway is an iron porphyrin oxygenase that opens the indole ring. The latter enzyme is highly inducible, its concentration rising almost 10-fold on a diet high in tryptophan. Kynurenine is the first key branch point intermediate in the pathway. Kynurenine undergoes deamniation in a standard transamination reaction yielding kynurenic acid. Kynurenic acid and metabolites have been shown to act as antiexcitotoxics and anticonvulsives. A second side branch reaction produces anthranilic acid plus alanine. Another equivalent of alanine is produced further along the main catabolic pathway, and it is the production of these alanine residues that allows tryptophan to be classified among the glucogenic and ketogenic amino acids. The second important branch point converts kynurenine into 2-amino-3-carboxymuconic semialdehyde, which has two fates. The main flow of carbon elements from this intermediate is to glutarate. An important side reaction in liver is a transamination and several rearrangements to produce limited amounts of nicotinic acid, which leads to production of a small amount of NAD+ and NADP+.

TargetActionsOrganism
UTryptophan--tRNA ligase, mitochondrial
inhibitor
Human
UTryptophan--tRNA ligase
inhibitor
Geobacillus stearothermophilus
UTryptophan--tRNA ligase, cytoplasmic
inhibitor
Human
Absorption
Not Available
Volume of distribution
Not Available
Protein binding
Not Available
Metabolism

Hepatic.

Route of elimination
Not Available
Half life
Not Available
Clearance
Not Available
Toxicity

Oral rat LD50: > 16 gm/kg. Investigated as a tumorigen, mutagen, reproductive effector. Symptoms of overdose include agitation, confusion, diarrhea, fever, overactive reflexes, poor coordination, restlessness, shivering, sweating, talking or acting with excitement you cannot control, trembling or shaking, twitching, and vomiting.

Affected organisms
  • Humans and other mammals
Pathways
PathwayCategory
Tryptophan MetabolismMetabolic
NAD MetabolismMetabolic
Tryptophan MetabolismMetabolic
tRNA Charging 2Metabolic
tRNA ChargingMetabolic
Tryptophan MetabolismMetabolic
Tryptophan Metabolism IIMetabolic
Inner Membrane TransportMetabolic
Trp OperonSignaling
Trp Operon InactivationSignaling
Tryptophan MetabolismMetabolic
Alanine MetabolismMetabolic
Tryptophan MetabolismMetabolic
Pharmacogenomic Effects/ADRs
Not Available

Interactions

Drug Interactions
DrugInteractionDrug group
2,5-Dimethoxy-4-ethylamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 2,5-Dimethoxy-4-ethylamphetamine.Experimental, Illicit
2,5-Dimethoxy-4-ethylthioamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 2,5-Dimethoxy-4-ethylthioamphetamine.Experimental
3,4-MethylenedioxyamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 3,4-Methylenedioxyamphetamine.Experimental, Illicit
4-Bromo-2,5-dimethoxyamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 4-Bromo-2,5-dimethoxyamphetamine.Experimental, Illicit
4-MethoxyamphetamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with 4-Methoxyamphetamine.Experimental, Illicit
5-methoxy-N,N-dimethyltryptamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 5-methoxy-N,N-dimethyltryptamine.Experimental, Illicit
7-NitroindazoleThe risk or severity of adverse effects can be increased when 7-Nitroindazole is combined with L-Tryptophan.Experimental
7,8-Dichloro-1,2,3,4-tetrahydroisoquinolineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with 7,8-Dichloro-1,2,3,4-tetrahydroisoquinoline.Experimental
AcepromazineThe risk or severity of adverse effects can be increased when Acepromazine is combined with L-Tryptophan.Approved, Vet Approved
AceprometazineThe risk or severity of adverse effects can be increased when Aceprometazine is combined with L-Tryptophan.Approved
AcetazolamideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Acetazolamide.Approved, Vet Approved
AcetophenazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Acetophenazine.Approved
Acetylglycinamide chloral hydrateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Acetylglycinamide chloral hydrate.Experimental
AdinazolamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Adinazolam.Approved
AdipiplonThe risk or severity of adverse effects can be increased when Adipiplon is combined with L-Tryptophan.Investigational
AgomelatineThe risk or severity of adverse effects can be increased when Agomelatine is combined with L-Tryptophan.Approved, Investigational
AlaproclateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Alaproclate.Experimental
AlcuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Alcuronium.Experimental
AlfaxaloneThe risk or severity of adverse effects can be increased when Alfaxalone is combined with L-Tryptophan.Vet Approved
AlfentanilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Alfentanil.Approved, Illicit
AlimemazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Alimemazine.Approved, Vet Approved
AllobarbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Allobarbital.Experimental
AllopregnanoloneThe risk or severity of adverse effects can be increased when Allopregnanolone is combined with L-Tryptophan.Investigational
AlmotriptanThe risk or severity of serotonin syndrome can be increased when Almotriptan is combined with L-Tryptophan.Approved, Investigational
AlosetronThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Alosetron.Approved, Withdrawn
AlphacetylmethadolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Alphacetylmethadol.Experimental, Illicit
AlphaprodineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Alphaprodine.Illicit
AlprazolamThe risk or severity of adverse effects can be increased when Alprazolam is combined with L-Tryptophan.Approved, Illicit, Investigational
AlprenololThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Alprenolol.Approved, Withdrawn
AlverineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Alverine.Approved, Investigational
AmantadineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Amantadine.Approved
AmikacinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Amikacin.Approved, Investigational, Vet Approved
AmineptineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Amineptine.Illicit, Withdrawn
AmisulprideThe risk or severity of adverse effects can be increased when Amisulpride is combined with L-Tryptophan.Approved, Investigational
AmitriptylineThe risk or severity of serotonin syndrome can be increased when Amitriptyline is combined with L-Tryptophan.Approved
AmitriptylinoxideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Amitriptylinoxide.Approved, Investigational
AmobarbitalThe risk or severity of adverse effects can be increased when Amobarbital is combined with L-Tryptophan.Approved, Illicit
AmoxapineThe risk or severity of serotonin syndrome can be increased when Amoxapine is combined with L-Tryptophan.Approved
AmperozideThe risk or severity of adverse effects can be increased when Amperozide is combined with L-Tryptophan.Experimental
AmphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Amphetamine.Approved, Illicit, Investigational
AniracetamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Aniracetam.Experimental
APD791The risk or severity of adverse effects can be increased when L-Tryptophan is combined with APD791.Investigational
ApomorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Apomorphine.Approved, Investigational
ApramycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Apramycin.Experimental, Vet Approved
AprobarbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Aprobarbital.Approved, Illicit
ApronalideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Apronalide.Experimental
Arbaclofen PlacarbilThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Arbaclofen Placarbil.Investigational
ArbekacinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Arbekacin.Approved, Investigational
AripiprazoleThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Aripiprazole.Approved, Investigational
Aripiprazole lauroxilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Aripiprazole lauroxil.Approved, Investigational
AsenapineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Asenapine.Approved
AtomoxetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Atomoxetine.Approved
AtracuriumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Atracurium.Approved, Experimental, Investigational
Atracurium besylateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Atracurium besylate.Approved
AzaperoneThe risk or severity of adverse effects can be increased when Azaperone is combined with L-Tryptophan.Investigational, Vet Approved
AZD-3043The risk or severity of adverse effects can be increased when L-Tryptophan is combined with AZD-3043.Investigational
AzelastineL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Azelastine.Approved
BaclofenThe risk or severity of adverse effects can be increased when Baclofen is combined with L-Tryptophan.Approved
BarbexacloneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Barbexaclone.Experimental
BarbitalThe risk or severity of adverse effects can be increased when Barbital is combined with L-Tryptophan.Illicit
BeclamideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Beclamide.Experimental
BekanamycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Bekanamycin.Experimental
BenactyzineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Benactyzine.Withdrawn
BenmoxinThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Benmoxin.Withdrawn
BenperidolThe risk or severity of adverse effects can be increased when Benperidol is combined with L-Tryptophan.Approved, Investigational
BenzoctamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Benzoctamine.Approved
BenzphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Benzphetamine.Approved, Illicit
Benzyl alcoholThe risk or severity of adverse effects can be increased when Benzyl alcohol is combined with L-Tryptophan.Approved
BezitramideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Bezitramide.Experimental, Illicit, Withdrawn
BifemelaneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Bifemelane.Experimental
BifeprunoxThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Bifeprunox.Investigational
BL-1020The risk or severity of adverse effects can be increased when L-Tryptophan is combined with BL-1020.Investigational
BlonanserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Blonanserin.Approved, Investigational
Botulinum Toxin Type AThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Botulinum Toxin Type A.Approved, Investigational
Botulinum Toxin Type BThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Botulinum Toxin Type B.Approved, Investigational
BrexpiprazoleThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Brexpiprazole.Approved, Investigational
BrimonidineBrimonidine may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved
BrivaracetamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Brivaracetam.Approved, Investigational
BrofaromineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Brofaromine.Experimental
BromazepamThe risk or severity of adverse effects can be increased when Bromazepam is combined with L-Tryptophan.Approved, Illicit, Investigational
BromisovalThe risk or severity of adverse effects can be increased when Bromisoval is combined with L-Tryptophan.Experimental
BromocriptineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Bromocriptine.Approved, Investigational
BromperidolThe risk or severity of adverse effects can be increased when Bromperidol is combined with L-Tryptophan.Approved, Investigational
BrompheniramineThe risk or severity of adverse effects can be increased when Brompheniramine is combined with L-Tryptophan.Approved
BrotizolamThe risk or severity of adverse effects can be increased when Brotizolam is combined with L-Tryptophan.Approved, Investigational, Withdrawn
BufotenineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Bufotenine.Experimental, Illicit
BuprenorphineL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.Approved, Illicit, Investigational, Vet Approved
BupropionThe risk or severity of serotonin syndrome can be increased when Bupropion is combined with L-Tryptophan.Approved
BuspironeThe risk or severity of serotonin syndrome can be increased when Buspirone is combined with L-Tryptophan.Approved, Investigational
ButabarbitalThe risk or severity of adverse effects can be increased when Butabarbital is combined with L-Tryptophan.Approved, Illicit
ButalbitalThe risk or severity of adverse effects can be increased when Butalbital is combined with L-Tryptophan.Approved, Illicit
ButaperazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Butaperazine.Experimental
ButethalThe risk or severity of adverse effects can be increased when Butethal is combined with L-Tryptophan.Approved, Illicit
ButorphanolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Butorphanol.Approved, Illicit, Vet Approved
ButriptylineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Butriptyline.Approved
CabergolineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cabergoline.Approved
CamazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Camazepam.Approved, Illicit
CannabidiolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cannabidiol.Approved, Investigational
CannabidivarinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cannabidivarin.Investigational
CapreomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Capreomycin.Approved
CaptodiameThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Captodiame.Approved, Investigational
CarbamazepineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Carbamazepine.Approved, Investigational
CarbinoxamineThe risk or severity of adverse effects can be increased when Carbinoxamine is combined with L-Tryptophan.Approved
CarbromalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Carbromal.Experimental
CarfentanilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Carfentanil.Illicit, Investigational, Vet Approved
CariprazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cariprazine.Approved, Investigational
CarisbamateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Carisbamate.Investigational
CarisoprodolThe risk or severity of adverse effects can be increased when Carisoprodol is combined with L-Tryptophan.Approved
CaroxazoneThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Caroxazone.Withdrawn
CathinoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cathinone.Illicit
CerlapirdineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cerlapirdine.Investigational
CetirizineThe risk or severity of adverse effects can be increased when Cetirizine is combined with L-Tryptophan.Approved
Chloral hydrateThe risk or severity of adverse effects can be increased when Chloral hydrate is combined with L-Tryptophan.Approved, Illicit, Investigational, Vet Approved
ChlordiazepoxideThe risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with L-Tryptophan.Approved, Illicit, Investigational
ChlormezanoneThe risk or severity of adverse effects can be increased when Chlormezanone is combined with L-Tryptophan.Approved, Investigational, Withdrawn
ChloroquineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Chloroquine.Approved, Investigational, Vet Approved
ChlorphenamineThe risk or severity of serotonin syndrome can be increased when Chlorphenamine is combined with L-Tryptophan.Approved
ChlorphenesinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Chlorphenesin.Approved, Experimental
ChlorphentermineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Chlorphentermine.Illicit, Withdrawn
ChlorproethazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Chlorproethazine.Experimental
ChlorpromazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Chlorpromazine.Approved, Investigational, Vet Approved
ChlorprothixeneThe risk or severity of adverse effects can be increased when Chlorprothixene is combined with L-Tryptophan.Approved, Investigational, Withdrawn
ChlortetracyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Chlortetracycline.Approved, Investigational, Vet Approved
ChlorzoxazoneThe risk or severity of adverse effects can be increased when Chlorzoxazone is combined with L-Tryptophan.Approved
CilansetronThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cilansetron.Investigational
CinitaprideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cinitapride.Approved, Investigational
CinolazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cinolazepam.Approved
CisaprideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cisapride.Approved, Investigational, Withdrawn
CisatracuriumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cisatracurium.Approved
CitalopramThe risk or severity of serotonin syndrome can be increased when Citalopram is combined with L-Tryptophan.Approved
ClemastineThe risk or severity of adverse effects can be increased when Clemastine is combined with L-Tryptophan.Approved, Investigational
ClidiniumThe risk or severity of adverse effects can be increased when Clidinium is combined with L-Tryptophan.Approved
ClindamycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Clindamycin.Approved, Vet Approved
ClobazamThe risk or severity of adverse effects can be increased when Clobazam is combined with L-Tryptophan.Approved, Illicit
clomethiazoleThe risk or severity of adverse effects can be increased when clomethiazole is combined with L-Tryptophan.Investigational
ClomipramineThe risk or severity of serotonin syndrome can be increased when Clomipramine is combined with L-Tryptophan.Approved, Investigational, Vet Approved
ClomocyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Clomocycline.Approved
ClonazepamThe risk or severity of adverse effects can be increased when Clonazepam is combined with L-Tryptophan.Approved, Illicit
ClonidineThe risk or severity of adverse effects can be increased when Clonidine is combined with L-Tryptophan.Approved
ClopenthixolThe risk or severity of adverse effects can be increased when Clopenthixol is combined with L-Tryptophan.Experimental
ClorazepateThe risk or severity of adverse effects can be increased when Clorazepate is combined with L-Tryptophan.Approved, Illicit
ClothiapineThe risk or severity of adverse effects can be increased when Clothiapine is combined with L-Tryptophan.Experimental
ClotiazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Clotiazepam.Approved, Illicit
CloxazolamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cloxazolam.Approved, Investigational
ClozapineThe risk or severity of adverse effects can be increased when Clozapine is combined with L-Tryptophan.Approved
CocaineThe risk or severity of serotonin syndrome can be increased when Cocaine is combined with L-Tryptophan.Approved, Illicit
CodeineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Codeine.Approved, Illicit
ColistimethateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Colistimethate.Approved, Vet Approved
ColistinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Colistin.Approved
CyamemazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cyamemazine.Approved
CyclizineThe risk or severity of adverse effects can be increased when Cyclizine is combined with L-Tryptophan.Approved
CyclobarbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cyclobarbital.Experimental
CyclobenzaprineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Cyclobenzaprine.Approved
CyclopropaneThe risk or severity of adverse effects can be increased when Cyclopropane is combined with L-Tryptophan.Experimental
CyclosporineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Cyclosporine.Approved, Investigational, Vet Approved
CyproheptadineThe risk or severity of adverse effects can be increased when Cyproheptadine is combined with L-Tryptophan.Approved
DantroleneThe risk or severity of adverse effects can be increased when Dantrolene is combined with L-Tryptophan.Approved, Investigational
DapiprazoleThe risk or severity of adverse effects can be increased when Dapiprazole is combined with L-Tryptophan.Approved
DapoxetineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dapoxetine.Investigational
DeanolThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Deanol.Experimental
DecamethoniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Decamethonium.Approved
DelorazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Delorazepam.Approved, Illicit, Investigational
DemeclocyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Demeclocycline.Approved
DeramciclaneThe risk or severity of adverse effects can be increased when Deramciclane is combined with L-Tryptophan.Investigational
DesfluraneThe risk or severity of adverse effects can be increased when Desflurane is combined with L-Tryptophan.Approved
DesipramineThe risk or severity of serotonin syndrome can be increased when Desipramine is combined with L-Tryptophan.Approved, Investigational
DesloratadineThe risk or severity of adverse effects can be increased when Desloratadine is combined with L-Tryptophan.Approved, Investigational
DesvenlafaxineThe risk or severity of serotonin syndrome can be increased when Desvenlafaxine is combined with L-Tryptophan.Approved, Investigational
DetomidineThe risk or severity of adverse effects can be increased when Detomidine is combined with L-Tryptophan.Vet Approved
DexbrompheniramineThe risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with L-Tryptophan.Approved
DexfenfluramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dexfenfluramine.Approved, Illicit, Investigational, Withdrawn
DexmedetomidineThe risk or severity of adverse effects can be increased when Dexmedetomidine is combined with L-Tryptophan.Approved, Vet Approved
DexmethylphenidateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dexmethylphenidate.Approved, Investigational
DextofisopamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Dextofisopam.Investigational
DextroamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dextroamphetamine.Approved, Illicit
DextromethorphanThe risk or severity of serotonin syndrome can be increased when Dextromethorphan is combined with L-Tryptophan.Approved
DextromoramideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dextromoramide.Experimental, Illicit
DextropropoxypheneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dextropropoxyphene.Approved, Illicit, Investigational, Withdrawn
DezocineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dezocine.Approved, Investigational
DiazepamThe risk or severity of adverse effects can be increased when Diazepam is combined with L-Tryptophan.Approved, Illicit, Investigational, Vet Approved
DibekacinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Dibekacin.Experimental
DibenzepinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dibenzepin.Experimental
DichloralphenazoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Dichloralphenazone.Approved, Illicit
Diethyl etherThe risk or severity of adverse effects can be increased when Diethyl ether is combined with L-Tryptophan.Experimental
DiethylpropionThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Diethylpropion.Approved, Illicit
DifenoxinThe risk or severity of adverse effects can be increased when Difenoxin is combined with L-Tryptophan.Approved, Illicit
DihydrocodeineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dihydrocodeine.Approved, Illicit
DihydroergotamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dihydroergotamine.Approved, Investigational
DihydroetorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dihydroetorphine.Experimental, Illicit
DihydromorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dihydromorphine.Experimental, Illicit
DihydrostreptomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Dihydrostreptomycin.Investigational, Vet Approved
DimenhydrinateThe risk or severity of adverse effects can be increased when Dimenhydrinate is combined with L-Tryptophan.Approved
DimetacrineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dimetacrine.Approved, Withdrawn
DimethyltryptamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dimethyltryptamine.Experimental, Illicit
DiphenhydramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Diphenhydramine.Approved, Investigational
DiphenoxylateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Diphenoxylate.Approved, Illicit
DixyrazineThe risk or severity of adverse effects can be increased when Dixyrazine is combined with L-Tryptophan.Experimental
DolasetronThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dolasetron.Approved, Investigational
Domoic AcidThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Domoic Acid.Experimental
DonepezilThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Donepezil.Approved
DoramectinThe risk or severity of adverse effects can be increased when Doramectin is combined with L-Tryptophan.Vet Approved
DosulepinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Dosulepin.Approved
DotarizineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Dotarizine.Investigational
DoxacuriumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Doxacurium.Approved
DoxefazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Doxefazepam.Experimental
DoxepinThe risk or severity of serotonin syndrome can be increased when Doxepin is combined with L-Tryptophan.Approved, Investigational
DoxycyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Doxycycline.Approved, Investigational, Vet Approved
DoxylamineDoxylamine may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved, Vet Approved
DPDPEThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with DPDPE.Experimental
DronabinolDronabinol may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved, Illicit
DroperidolDroperidol may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved, Vet Approved
DrotebanolThe risk or severity of adverse effects can be increased when Drotebanol is combined with L-Tryptophan.Experimental, Illicit
DuloxetineThe risk or severity of serotonin syndrome can be increased when Duloxetine is combined with L-Tryptophan.Approved
DyclonineThe risk or severity of adverse effects can be increased when Dyclonine is combined with L-Tryptophan.Approved
EcopipamThe risk or severity of adverse effects can be increased when Ecopipam is combined with L-Tryptophan.Investigational
EdivoxetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Edivoxetine.Investigational
EfavirenzThe risk or severity of adverse effects can be increased when Efavirenz is combined with L-Tryptophan.Approved, Investigational
EletriptanThe risk or severity of serotonin syndrome can be increased when Eletriptan is combined with L-Tryptophan.Approved, Investigational
EltanoloneThe risk or severity of adverse effects can be increased when Eltanolone is combined with L-Tryptophan.Investigational
EltoprazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Eltoprazine.Investigational
EluxadolineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Eluxadoline.Approved, Investigational
EmeproniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Emepronium.Experimental
EmylcamateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Emylcamate.Experimental
EnfluraneThe risk or severity of adverse effects can be increased when Enflurane is combined with L-Tryptophan.Approved, Investigational, Vet Approved
EntacaponeThe risk or severity of adverse effects can be increased when Entacapone is combined with L-Tryptophan.Approved, Investigational
EperisoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Eperisone.Approved, Investigational
EpinastineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Epinastine.Approved, Investigational
EplivanserinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Eplivanserin.Investigational
Ergoloid mesylateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ergoloid mesylate.Approved
ErgonovineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ergonovine.Approved
ErgotamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ergotamine.Approved
EscitalopramThe risk or severity of serotonin syndrome can be increased when Escitalopram is combined with L-Tryptophan.Approved, Investigational
EslicarbazepineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Eslicarbazepine.Approved
Eslicarbazepine acetateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Eslicarbazepine acetate.Approved
EsmirtazapineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Esmirtazapine.Investigational
EsreboxetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Esreboxetine.Investigational
EstazolamThe risk or severity of adverse effects can be increased when Estazolam is combined with L-Tryptophan.Approved, Illicit
EszopicloneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Eszopiclone.Approved, Investigational
Etacrynic acidThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Etacrynic acid.Approved, Investigational
EthadioneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ethadione.Experimental
EthanolL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Ethanol.Approved
EthchlorvynolThe risk or severity of adverse effects can be increased when Ethchlorvynol is combined with L-Tryptophan.Approved, Illicit, Withdrawn
EthosuximideThe risk or severity of adverse effects can be increased when Ethosuximide is combined with L-Tryptophan.Approved
EthotoinThe risk or severity of adverse effects can be increased when Ethotoin is combined with L-Tryptophan.Approved
Ethyl carbamateThe risk or severity of adverse effects can be increased when Ethyl carbamate is combined with L-Tryptophan.Withdrawn
Ethyl chlorideThe risk or severity of adverse effects can be increased when Ethyl chloride is combined with L-Tryptophan.Approved, Experimental, Investigational
Ethyl loflazepateThe risk or severity of adverse effects can be increased when Ethyl loflazepate is combined with L-Tryptophan.Approved, Illicit
EthylmorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ethylmorphine.Approved, Illicit
EtifoxineThe risk or severity of adverse effects can be increased when Etifoxine is combined with L-Tryptophan.Investigational, Withdrawn
EtiracetamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Etiracetam.Investigational
EtizolamThe risk or severity of adverse effects can be increased when Etizolam is combined with L-Tryptophan.Approved
EtomidateThe risk or severity of adverse effects can be increased when Etomidate is combined with L-Tryptophan.Approved
EtoperidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Etoperidone.Withdrawn
EtorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Etorphine.Illicit, Vet Approved
EzogabineThe risk or severity of adverse effects can be increased when Ezogabine is combined with L-Tryptophan.Approved, Investigational
FabomotizoleThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Fabomotizole.Experimental
Fazadinium bromideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Fazadinium bromide.Experimental
FebarbamateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Febarbamate.Experimental
FelbamateThe risk or severity of adverse effects can be increased when Felbamate is combined with L-Tryptophan.Approved
FencamfamineThe risk or severity of adverse effects can be increased when Fencamfamine is combined with L-Tryptophan.Approved, Illicit, Withdrawn
FenfluramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Fenfluramine.Approved, Illicit, Investigational, Withdrawn
FentanylThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Fentanyl.Approved, Illicit, Investigational, Vet Approved
FenyramidolThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Fenyramidol.Experimental
FexofenadineThe risk or severity of adverse effects can be increased when Fexofenadine is combined with L-Tryptophan.Approved, Investigational
FlibanserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Flibanserin.Approved, Investigational
FluanisoneThe risk or severity of adverse effects can be increased when Fluanisone is combined with L-Tryptophan.Experimental
FludiazepamThe risk or severity of adverse effects can be increased when Fludiazepam is combined with L-Tryptophan.Approved, Illicit
FlunarizineThe risk or severity of adverse effects can be increased when Flunarizine is combined with L-Tryptophan.Approved
FlunitrazepamThe risk or severity of adverse effects can be increased when Flunitrazepam is combined with L-Tryptophan.Approved, Illicit
FluoxetineThe risk or severity of serotonin syndrome can be increased when Fluoxetine is combined with L-Tryptophan.Approved, Vet Approved
FlupentixolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Flupentixol.Approved, Investigational, Withdrawn
FluphenazineThe risk or severity of adverse effects can be increased when Fluphenazine is combined with L-Tryptophan.Approved
FlurazepamThe risk or severity of adverse effects can be increased when Flurazepam is combined with L-Tryptophan.Approved, Illicit, Investigational
FluspirileneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Fluspirilene.Approved, Investigational
Fluticasone propionateThe risk or severity of adverse effects can be increased when Fluticasone propionate is combined with L-Tryptophan.Approved
FluvoxamineThe risk or severity of serotonin syndrome can be increased when Fluvoxamine is combined with L-Tryptophan.Approved, Investigational
FosphenytoinThe risk or severity of adverse effects can be increased when Fosphenytoin is combined with L-Tryptophan.Approved, Investigational
FospropofolThe risk or severity of adverse effects can be increased when Fospropofol is combined with L-Tryptophan.Approved, Illicit, Investigational
FramycetinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Framycetin.Approved
FrovatriptanThe risk or severity of serotonin syndrome can be increased when Frovatriptan is combined with L-Tryptophan.Approved, Investigational
FurazolidoneThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Furazolidone.Approved, Investigational, Vet Approved
GabapentinThe risk or severity of adverse effects can be increased when Gabapentin is combined with L-Tryptophan.Approved, Investigational
Gabapentin enacarbilThe risk or severity of adverse effects can be increased when Gabapentin enacarbil is combined with L-Tryptophan.Approved, Investigational
GaboxadolThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gaboxadol.Investigational
GallamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gallamine.Experimental
Gallamine TriethiodideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gallamine Triethiodide.Approved
Gamma hydroxybutyric acidThe risk or severity of adverse effects can be increased when Gamma hydroxybutyric acid is combined with L-Tryptophan.Approved, Illicit, Investigational
Gantacurium ChlorideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gantacurium Chloride.Investigational
GedocarnilThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gedocarnil.Experimental
GeneticinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Geneticin.Experimental
GentamicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Gentamicin.Approved, Vet Approved
GENTAMICIN C1AThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with GENTAMICIN C1A.Experimental
GepefrineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Gepefrine.Experimental
GepironeThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Gepirone.Investigational
GlutethimideThe risk or severity of adverse effects can be increased when Glutethimide is combined with L-Tryptophan.Approved, Illicit
GranisetronThe risk or severity of serotonin syndrome can be increased when Granisetron is combined with L-Tryptophan.Approved, Investigational
GuanfacineThe risk or severity of adverse effects can be increased when Guanfacine is combined with L-Tryptophan.Approved, Investigational
HalazepamThe risk or severity of adverse effects can be increased when Halazepam is combined with L-Tryptophan.Approved, Illicit, Withdrawn
HaloperidolThe risk or severity of adverse effects can be increased when Haloperidol is combined with L-Tryptophan.Approved
HalothaneThe risk or severity of adverse effects can be increased when Halothane is combined with L-Tryptophan.Approved, Vet Approved
HarmalineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Harmaline.Experimental
HeptabarbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Heptabarbital.Approved
HeroinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Heroin.Approved, Illicit, Investigational
HexafluroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hexafluronium.Approved
HexamethoniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hexamethonium.Experimental
HexapropymateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hexapropymate.Experimental
HexobarbitalThe risk or severity of adverse effects can be increased when Hexobarbital is combined with L-Tryptophan.Approved
HydracarbazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Hydracarbazine.Experimental
HydrocodoneL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.Approved, Illicit, Investigational
HydromorphoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Hydromorphone.Approved, Illicit
HydroxyamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Hydroxyamphetamine.Approved
HydroxyzineHydroxyzine may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved
Hygromycin BThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hygromycin B.Vet Approved
HypericinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Hypericin.Investigational
IdalopirdineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Idalopirdine.Investigational
IfenprodilThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ifenprodil.Approved, Investigational, Withdrawn
IferanserinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iferanserin.Investigational
IloperidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Iloperidone.Approved
ImagabalinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Imagabalin.Investigational
ImipramineThe risk or severity of serotonin syndrome can be increased when Imipramine is combined with L-Tryptophan.Approved
Imipramine oxideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Imipramine oxide.Experimental
IndalpineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Indalpine.Investigational, Withdrawn
IndiplonThe risk or severity of adverse effects can be increased when Indiplon is combined with L-Tryptophan.Investigational
Iofetamine I-123The risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Iofetamine I-123.Approved
IprazochromeThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iprazochrome.Experimental
IprindoleThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Iprindole.Experimental
IproclozideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Iproclozide.Withdrawn
IproniazidThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Iproniazid.Withdrawn
IsepamicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Isepamicin.Experimental
IsocarboxazidThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Isocarboxazid.Approved
IsofluraneThe risk or severity of adverse effects can be increased when Isoflurane is combined with L-Tryptophan.Approved, Vet Approved
IsoniazidThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Isoniazid.Approved, Investigational
KanamycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Kanamycin.Approved, Investigational, Vet Approved
KetamineThe risk or severity of adverse effects can be increased when Ketamine is combined with L-Tryptophan.Approved, Vet Approved
KetanserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ketanserin.Investigational
KetazolamThe risk or severity of adverse effects can be increased when Ketazolam is combined with L-Tryptophan.Approved
KetobemidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ketobemidone.Approved, Investigational
LacosamideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lacosamide.Approved
LamotrigineThe risk or severity of adverse effects can be increased when Lamotrigine is combined with L-Tryptophan.Approved, Investigational
LanicemineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lanicemine.Investigational
LasmiditanThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lasmiditan.Investigational
LevetiracetamThe risk or severity of adverse effects can be increased when Levetiracetam is combined with L-Tryptophan.Approved, Investigational
LevocabastineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Levocabastine.Approved, Investigational
LevocetirizineThe risk or severity of adverse effects can be increased when Levocetirizine is combined with L-Tryptophan.Approved
LevodopaThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Levodopa.Approved
Levomethadyl acetateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Levomethadyl acetate.Approved, Investigational
LevomilnacipranThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Levomilnacipran.Approved, Investigational
LevorphanolThe risk or severity of serotonin syndrome can be increased when Levorphanol is combined with L-Tryptophan.Approved
LincomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lincomycin.Approved, Vet Approved
LinezolidThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Linezolid.Approved, Investigational
LisdexamfetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lisdexamfetamine.Approved, Investigational
LisurideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lisuride.Approved, Investigational
Lithium carbonateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lithium carbonate.Approved
Lithium cationThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lithium cation.Experimental
LofentanilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lofentanil.Illicit
LofepramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lofepramine.Experimental
LofexidineThe therapeutic efficacy of L-Tryptophan can be increased when used in combination with Lofexidine.Approved, Investigational
LoprazolamThe risk or severity of adverse effects can be increased when Loprazolam is combined with L-Tryptophan.Experimental
LoratadineThe risk or severity of adverse effects can be increased when Loratadine is combined with L-Tryptophan.Approved, Investigational
LorazepamThe risk or severity of adverse effects can be increased when Lorazepam is combined with L-Tryptophan.Approved
LorcaserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lorcaserin.Approved
LormetazepamThe risk or severity of adverse effects can be increased when Lormetazepam is combined with L-Tryptophan.Approved
LortalamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lortalamine.Experimental
LoxapineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Loxapine.Approved
LumateperoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lumateperone.Investigational
LurasidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lurasidone.Approved, Investigational
LymecyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Lymecycline.Approved, Investigational
Lysergic Acid DiethylamideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Lysergic Acid Diethylamide.Illicit, Investigational, Withdrawn
m-ChlorophenylpiperazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with m-Chlorophenylpiperazine.Investigational
Magnesium acetateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium acetate.Approved
Magnesium acetate tetrahydrateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium acetate tetrahydrate.Approved
Magnesium Aluminum SilicateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium Aluminum Silicate.Approved
Magnesium aspartateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium aspartate.Experimental
Magnesium carbonateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium carbonate.Approved, Investigational
Magnesium cationThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium cation.Approved, Nutraceutical
Magnesium chlorideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium chloride.Approved
Magnesium citrateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium citrate.Approved
Magnesium gluconateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium gluconate.Approved, Investigational
Magnesium glycinateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium glycinate.Approved
Magnesium hydroxideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium hydroxide.Approved, Investigational
Magnesium orotateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium orotate.Experimental
Magnesium oxideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium oxide.Approved
Magnesium phosphateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium phosphate.Experimental
Magnesium silicateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium silicate.Approved
Magnesium stearateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium stearate.Investigational
Magnesium sulfateThe therapeutic efficacy of L-Tryptophan can be increased when used in combination with Magnesium sulfate.Approved, Investigational, Vet Approved
Magnesium TrisilicateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Magnesium Trisilicate.Approved
MaprotilineThe risk or severity of serotonin syndrome can be increased when Maprotiline is combined with L-Tryptophan.Approved, Investigational
MazindolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Mazindol.Approved, Investigational
MebanazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Mebanazine.Withdrawn
MebicarThe risk or severity of adverse effects can be increased when Mebicar is combined with L-Tryptophan.Experimental
MebutamateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mebutamate.Approved
MecamylamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mecamylamine.Approved, Investigational
MeclizineThe risk or severity of adverse effects can be increased when Meclizine is combined with L-Tryptophan.Approved
MedazepamThe risk or severity of adverse effects can be increased when Medazepam is combined with L-Tryptophan.Experimental
MedetomidineThe risk or severity of adverse effects can be increased when Medetomidine is combined with L-Tryptophan.Vet Approved
MedifoxamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Medifoxamine.Experimental
MelatoninThe risk or severity of adverse effects can be increased when Melatonin is combined with L-Tryptophan.Approved, Nutraceutical, Vet Approved
MelitracenThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Melitracen.Experimental, Investigational
MelperoneThe risk or severity of adverse effects can be increased when Melperone is combined with L-Tryptophan.Approved, Investigational
MephedroneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Mephedrone.Investigational
MephenesinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mephenesin.Approved
MephenoxaloneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mephenoxalone.Experimental
MephentermineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Mephentermine.Approved
MephenytoinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mephenytoin.Approved, Investigational, Withdrawn
MeprobamateThe risk or severity of adverse effects can be increased when Meprobamate is combined with L-Tryptophan.Approved, Illicit
MeptazinolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Meptazinol.Experimental
MesoridazineThe risk or severity of adverse effects can be increased when Mesoridazine is combined with L-Tryptophan.Approved, Investigational
MetaxaloneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Metaxalone.Approved
MetergolineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Metergoline.Experimental
MethacyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Methacycline.Approved, Investigational
MethadoneThe risk or severity of adverse effects can be increased when Methadone is combined with L-Tryptophan.Approved
Methadyl acetateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Methadyl acetate.Approved, Illicit
MethamphetamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Methamphetamine.Approved, Illicit
MethapyrileneThe risk or severity of adverse effects can be increased when Methapyrilene is combined with L-Tryptophan.Withdrawn
MethaqualoneThe risk or severity of adverse effects can be increased when Methaqualone is combined with L-Tryptophan.Illicit, Withdrawn
MetharbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Metharbital.Withdrawn
MethocarbamolThe risk or severity of adverse effects can be increased when Methocarbamol is combined with L-Tryptophan.Approved, Vet Approved
MethohexitalThe risk or severity of adverse effects can be increased when Methohexital is combined with L-Tryptophan.Approved
MethotrimeprazineL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.Approved, Investigational
MethoxyfluraneThe risk or severity of adverse effects can be increased when Methoxyflurane is combined with L-Tryptophan.Approved, Investigational, Vet Approved
MethoxyphenamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Methoxyphenamine.Experimental
MethsuximideThe risk or severity of adverse effects can be increased when Methsuximide is combined with L-Tryptophan.Approved
Methylene blueThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Methylene blue.Approved, Investigational
MethylpentynolThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Methylpentynol.Experimental
MethylphenidateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Methylphenidate.Approved, Investigational
MethylphenobarbitalThe risk or severity of adverse effects can be increased when Methylphenobarbital is combined with L-Tryptophan.Approved
MethylthioniniumThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Methylthioninium.Experimental, Investigational
MethyprylonThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Methyprylon.Approved, Illicit, Withdrawn
MethysergideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Methysergide.Approved
MetoclopramideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Metoclopramide.Approved, Investigational
MetocurineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Metocurine.Approved
Metocurine IodideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Metocurine Iodide.Approved, Withdrawn
MetyrosineL-Tryptophan may increase the sedative activities of Metyrosine.Approved
MianserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Mianserin.Approved, Investigational
MicronomicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Micronomicin.Experimental
MidazolamThe risk or severity of adverse effects can be increased when Midazolam is combined with L-Tryptophan.Approved, Illicit
MidomafetamineThe risk or severity of serotonin syndrome can be increased when Midomafetamine is combined with L-Tryptophan.Experimental, Illicit, Investigational
MilnacipranThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Milnacipran.Approved, Investigational
MinaprineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Minaprine.Approved
MinocyclineMinocycline may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved, Investigational
MirtazapineL-Tryptophan may increase the serotonergic activities of Mirtazapine.Approved
MivacuriumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mivacurium.Approved
MK-212The risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with MK-212.Investigational
MMDAThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with MMDA.Experimental, Illicit
MoclobemideThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Moclobemide.Approved, Investigational
MolindoneThe risk or severity of adverse effects can be increased when Molindone is combined with L-Tryptophan.Approved
MoperoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Moperone.Experimental
MoricizineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Moricizine.Approved, Investigational, Withdrawn
MorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Morphine.Approved, Investigational
MosapramineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Mosapramine.Experimental
MosaprideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Mosapride.Investigational
MRK-409The risk or severity of adverse effects can be increased when L-Tryptophan is combined with MRK-409.Experimental
N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with N-(2-hydroxybenzyl)-2,5-dimethoxy-4-cyanophenylethylamine.Experimental
NabiloneNabilone may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved, Investigational
NaftidrofurylThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Naftidrofuryl.Experimental
NalbuphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Nalbuphine.Approved
NaltrexoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Naltrexone.Approved, Investigational, Vet Approved
NaluzotanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Naluzotan.Investigational
NaratriptanThe risk or severity of serotonin syndrome can be increased when Naratriptan is combined with L-Tryptophan.Approved, Investigational
NaronaprideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Naronapride.Investigational
NeamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Neamine.Experimental
NefazodoneThe risk or severity of serotonin syndrome can be increased when Nefazodone is combined with L-Tryptophan.Approved, Withdrawn
NefiracetamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Nefiracetam.Investigational
NeocitrullamonThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Neocitrullamon.Experimental
NeomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Neomycin.Approved, Vet Approved
NeosaxitoxinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Neosaxitoxin.Investigational
NetilmicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Netilmicin.Approved, Investigational
NialamideThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Nialamide.Withdrawn
NiaprazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Niaprazine.Experimental
NicomorphineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Nicomorphine.Experimental
NisoxetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Nisoxetine.Experimental
NitrazepamThe risk or severity of adverse effects can be increased when Nitrazepam is combined with L-Tryptophan.Approved
Nitrous oxideThe risk or severity of adverse effects can be increased when Nitrous oxide is combined with L-Tryptophan.Approved, Vet Approved
NomifensineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Nomifensine.Withdrawn
NordazepamThe risk or severity of adverse effects can be increased when Nordazepam is combined with L-Tryptophan.Approved
NormethadoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Normethadone.Approved, Illicit
NortriptylineThe risk or severity of serotonin syndrome can be increased when Nortriptyline is combined with L-Tryptophan.Approved
NutmegThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Nutmeg.Approved
OcinaplonThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ocinaplon.Investigational
OctamoxinThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Octamoxin.Withdrawn
OlanzapineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Olanzapine.Approved, Investigational
OlopatadineThe risk or severity of adverse effects can be increased when Olopatadine is combined with L-Tryptophan.Approved
OndansetronThe risk or severity of serotonin syndrome can be increased when Ondansetron is combined with L-Tryptophan.Approved
OpipramolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Opipramol.Investigational
OpiumThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Opium.Approved, Illicit
OrphenadrineL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Orphenadrine.Approved
OrvepitantThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Orvepitant.Investigational
OsanetantThe risk or severity of adverse effects can be increased when Osanetant is combined with L-Tryptophan.Investigational
OxaflozaneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxaflozane.Experimental
OxaprotilineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Oxaprotiline.Experimental
OxazepamThe risk or severity of adverse effects can be increased when Oxazepam is combined with L-Tryptophan.Approved
Oxazepam acetateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxazepam acetate.Experimental
OxcarbazepineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxcarbazepine.Approved
OxiracetamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxiracetam.Experimental
OxitriptanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxitriptan.Approved, Investigational, Nutraceutical
OxprenololThe risk or severity of adverse effects can be increased when Oxprenolol is combined with L-Tryptophan.Approved
OxycodoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Oxycodone.Approved, Illicit, Investigational
OxymorphoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Oxymorphone.Approved, Investigational, Vet Approved
OxypertineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxypertine.Experimental
OxytetracyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Oxytetracycline.Approved, Investigational, Vet Approved
PagocloneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pagoclone.Investigational
PaliperidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Paliperidone.Approved
PalonosetronThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Palonosetron.Approved, Investigational
PancuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pancuronium.Approved
ParaldehydeL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.Approved, Investigational
ParamethadioneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Paramethadione.Approved
PargylineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Pargyline.Approved
ParomomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Paromomycin.Approved, Investigational
ParoxetineThe risk or severity of serotonin syndrome can be increased when Paroxetine is combined with L-Tryptophan.Approved, Investigational
PenbutololThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Penbutolol.Approved, Investigational
PenfluridolThe risk or severity of adverse effects can be increased when Penfluridol is combined with L-Tryptophan.Experimental
PenimepicyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Penimepicycline.Experimental
PentazocineThe risk or severity of serotonin syndrome can be increased when Pentazocine is combined with L-Tryptophan.Approved, Vet Approved
PentobarbitalThe risk or severity of adverse effects can be increased when Pentobarbital is combined with L-Tryptophan.Approved, Investigational, Vet Approved
PerampanelPerampanel may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved
PerazineThe risk or severity of adverse effects can be increased when Perazine is combined with L-Tryptophan.Approved, Investigational
PergolideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pergolide.Approved, Investigational, Vet Approved, Withdrawn
PerospironeThe risk or severity of adverse effects can be increased when Perospirone is combined with L-Tryptophan.Approved
PerphenazineThe risk or severity of adverse effects can be increased when Perphenazine is combined with L-Tryptophan.Approved
Perphenazine enanthateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Perphenazine enanthate.Experimental
PethidineThe risk or severity of serotonin syndrome can be increased when Pethidine is combined with L-Tryptophan.Approved
PhenacemideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenacemide.Approved
PhenazocineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Phenazocine.Experimental
PhencyclidineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phencyclidine.Illicit
PhenelzineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Phenelzine.Approved
PhenethylamineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenethylamine.Experimental
PheneturideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pheneturide.Experimental
PhenibutThe risk or severity of adverse effects can be increased when Phenibut is combined with L-Tryptophan.Experimental
PheniprazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Pheniprazine.Withdrawn
PhenobarbitalThe risk or severity of adverse effects can be increased when Phenobarbital is combined with L-Tryptophan.Approved, Investigational
PhenoperidineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Phenoperidine.Experimental
PhenoxypropazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Phenoxypropazine.Withdrawn
PhenprobamateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phenprobamate.Experimental
PhensuximideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Phensuximide.Approved
PhentermineThe risk or severity of serotonin syndrome can be increased when Phentermine is combined with L-Tryptophan.Approved, Illicit
PhenytoinThe risk or severity of adverse effects can be increased when Phenytoin is combined with L-Tryptophan.Approved, Vet Approved
PiclozotanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Piclozotan.Investigational
PimavanserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pimavanserin.Approved, Investigational
PimozideThe risk or severity of adverse effects can be increased when Pimozide is combined with L-Tryptophan.Approved
PinazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pinazepam.Experimental
PindololThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pindolol.Approved, Investigational
PipamperoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pipamperone.Approved, Investigational
PipecuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pipecuronium.Approved
PipotiazineThe risk or severity of adverse effects can be increased when Pipotiazine is combined with L-Tryptophan.Approved, Investigational
PiritramideThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Piritramide.Approved, Investigational
PirlimycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pirlimycin.Vet Approved
PirlindoleThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Pirlindole.Approved
PivagabineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pivagabine.Investigational
PivhydrazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Pivhydrazine.Withdrawn
PizotifenThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pizotifen.Approved
PlazomicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Plazomicin.Approved, Investigational
Polymyxin B SulfateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Polymyxin B Sulfate.Approved, Vet Approved
PomalidomideThe risk or severity of adverse effects can be increased when Pomalidomide is combined with L-Tryptophan.Approved
PramipexoleL-Tryptophan may increase the sedative activities of Pramipexole.Approved, Investigational
PrazepamThe risk or severity of adverse effects can be increased when Prazepam is combined with L-Tryptophan.Approved, Illicit
PregabalinThe therapeutic efficacy of L-Tryptophan can be increased when used in combination with Pregabalin.Approved, Illicit, Investigational
PridinolThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pridinol.Experimental
PrimidoneThe risk or severity of adverse effects can be increased when Primidone is combined with L-Tryptophan.Approved, Vet Approved
ProcainamideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Procainamide.Approved
ProcaineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Procaine.Approved, Investigational, Vet Approved
ProcarbazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Procarbazine.Approved, Investigational
ProchlorperazineThe risk or severity of adverse effects can be increased when Prochlorperazine is combined with L-Tryptophan.Approved, Vet Approved
ProgabideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Progabide.Approved, Investigational
PromazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Promazine.Approved, Vet Approved
PromethazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Promethazine.Approved, Investigational
PropanididThe risk or severity of adverse effects can be increased when Propanidid is combined with L-Tryptophan.Experimental
PropericiazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Propericiazine.Approved, Investigational
PropiomazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Propiomazine.Approved
PropiopromazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Propiopromazine.Vet Approved
PropofolThe risk or severity of adverse effects can be increased when Propofol is combined with L-Tryptophan.Approved, Investigational, Vet Approved
ProthipendylThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Prothipendyl.Investigational
ProtriptylineThe risk or severity of serotonin syndrome can be increased when Protriptyline is combined with L-Tryptophan.Approved
ProxibarbalThe risk or severity of adverse effects can be increased when Proxibarbal is combined with L-Tryptophan.Experimental
PRX-08066The risk or severity of adverse effects can be increased when L-Tryptophan is combined with PRX-08066.Investigational
PseudoephedrineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Pseudoephedrine.Approved
PsilocybineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Psilocybine.Investigational
PuromycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Puromycin.Experimental
PyrantelThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pyrantel.Approved, Vet Approved
PyrithyldioneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Pyrithyldione.Experimental
QuazepamThe risk or severity of adverse effects can be increased when Quazepam is combined with L-Tryptophan.Approved, Illicit
QuetiapineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Quetiapine.Approved
QuinidineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Quinidine.Approved, Investigational
QuinineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Quinine.Approved
QuinupramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Quinupramine.Experimental
RacloprideThe risk or severity of adverse effects can be increased when Raclopride is combined with L-Tryptophan.Investigational
RamelteonThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ramelteon.Approved, Investigational
RamosetronThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ramosetron.Approved, Investigational
RapacuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rapacuronium.Approved, Withdrawn
RasagilineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Rasagiline.Approved
ReboxetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Reboxetine.Approved, Investigational
RemacemideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Remacemide.Investigational
RemifentanilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Remifentanil.Approved
RemoxiprideThe risk or severity of adverse effects can be increased when Remoxipride is combined with L-Tryptophan.Approved, Withdrawn
RenzaprideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Renzapride.Investigational
RepinotanThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Repinotan.Investigational
ReposalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Reposal.Approved
ReserpineThe risk or severity of adverse effects can be increased when Reserpine is combined with L-Tryptophan.Approved, Investigational
RibostamycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Ribostamycin.Approved, Investigational
RiluzoleThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Riluzole.Approved, Investigational
RisperidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Risperidone.Approved, Investigational
RitanserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ritanserin.Investigational
RitobegronThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ritobegron.Investigational
RitonavirThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ritonavir.Approved, Investigational
RizatriptanThe risk or severity of serotonin syndrome can be increased when Rizatriptan is combined with L-Tryptophan.Approved
RocuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rocuronium.Approved
RolipramThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rolipram.Investigational
RolitetracyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Rolitetracycline.Approved
RomifidineThe risk or severity of adverse effects can be increased when Romifidine is combined with L-Tryptophan.Vet Approved
RopiniroleL-Tryptophan may increase the sedative activities of Ropinirole.Approved, Investigational
RotigotineL-Tryptophan may increase the sedative activities of Rotigotine.Approved
RP-5063The risk or severity of adverse effects can be increased when L-Tryptophan is combined with RP-5063.Investigational
RufinamideThe risk or severity of adverse effects can be increased when Rufinamide is combined with L-Tryptophan.Approved
SafinamideThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Safinamide.Approved, Investigational
SafrazineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Safrazine.Withdrawn
SaredutantThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Saredutant.Investigational
SarpogrelateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Sarpogrelate.Investigational
ScopolamineThe risk or severity of adverse effects can be increased when Scopolamine is combined with L-Tryptophan.Approved, Investigational
SecobarbitalThe risk or severity of adverse effects can be increased when Secobarbital is combined with L-Tryptophan.Approved, Vet Approved
SelegilineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Selegiline.Approved, Investigational, Vet Approved
SerotoninThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Serotonin.Investigational, Nutraceutical
SertindoleThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Sertindole.Approved, Investigational, Withdrawn
SertralineThe risk or severity of serotonin syndrome can be increased when Sertraline is combined with L-Tryptophan.Approved
SevofluraneThe risk or severity of adverse effects can be increased when Sevoflurane is combined with L-Tryptophan.Approved, Vet Approved
SibutramineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Sibutramine.Approved, Illicit, Investigational, Withdrawn
SisomicinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Sisomicin.Investigational
Sodium oxybateSodium oxybate may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved
St. John's WortThe risk or severity of serotonin syndrome can be increased when St. John's Wort is combined with L-Tryptophan.Approved, Investigational, Nutraceutical
StiripentolThe risk or severity of adverse effects can be increased when Stiripentol is combined with L-Tryptophan.Approved
StreptomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Streptomycin.Approved, Vet Approved
StyramateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Styramate.Experimental
SuccinylcholineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Succinylcholine.Approved
SufentanilThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Sufentanil.Approved, Investigational
SulpirideThe risk or severity of adverse effects can be increased when Sulpiride is combined with L-Tryptophan.Approved, Investigational
SulthiameThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Sulthiame.Experimental
SultoprideThe risk or severity of adverse effects can be increased when Sultopride is combined with L-Tryptophan.Experimental
SumatriptanThe risk or severity of serotonin syndrome can be increased when Sumatriptan is combined with L-Tryptophan.Approved, Investigational
SuvorexantL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.Approved, Investigational
TalbutalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Talbutal.Approved, Illicit
TalopramThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Talopram.Experimental
TandospironeThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Tandospirone.Investigational
TapentadolTapentadol may increase the central nervous system depressant (CNS depressant) activities of L-Tryptophan.Approved
TasimelteonThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tasimelteon.Approved, Investigational
TD-8954The risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with TD-8954.Investigational
Tedizolid phosphateThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Tedizolid phosphate.Approved
TegaserodThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Tegaserod.Approved, Investigational, Withdrawn
TemazepamThe risk or severity of adverse effects can be increased when Temazepam is combined with L-Tryptophan.Approved, Investigational
TetracyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tetracycline.Approved, Vet Approved
TetrahydrocannabivarinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tetrahydrocannabivarin.Investigational
TetrahydropalmatineThe risk or severity of adverse effects can be increased when Tetrahydropalmatine is combined with L-Tryptophan.Investigational
TetrazepamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tetrazepam.Experimental
TetrodotoxinThe risk or severity of adverse effects can be increased when Tetrodotoxin is combined with L-Tryptophan.Investigational
ThalidomideL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.Approved, Investigational, Withdrawn
ThiamylalThe risk or severity of adverse effects can be increased when Thiamylal is combined with L-Tryptophan.Approved, Vet Approved
ThiazinamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Thiazinam.Experimental
ThiethylperazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Thiethylperazine.Withdrawn
ThiocolchicosideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Thiocolchicoside.Approved, Investigational
ThiopentalThe risk or severity of adverse effects can be increased when Thiopental is combined with L-Tryptophan.Approved, Vet Approved
ThiopropazateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Thiopropazate.Experimental
ThioproperazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Thioproperazine.Approved
ThioridazineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Thioridazine.Approved, Withdrawn
ThiothixeneThe risk or severity of adverse effects can be increased when Thiothixene is combined with L-Tryptophan.Approved
TiagabineThe risk or severity of adverse effects can be increased when Tiagabine is combined with L-Tryptophan.Approved, Investigational
TianeptineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Tianeptine.Approved, Investigational
TiaprideThe risk or severity of adverse effects can be increased when Tiapride is combined with L-Tryptophan.Approved, Investigational
TigecyclineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tigecycline.Approved
TiletamineThe risk or severity of adverse effects can be increased when Tiletamine is combined with L-Tryptophan.Vet Approved
TilidineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Tilidine.Experimental
TizanidineThe risk or severity of adverse effects can be increased when Tizanidine is combined with L-Tryptophan.Approved, Investigational
TobramycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tobramycin.Approved, Investigational
TofisopamThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tofisopam.Approved
TolcaponeThe risk or severity of adverse effects can be increased when Tolcapone is combined with L-Tryptophan.Approved, Withdrawn
ToloxatoneThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Toloxatone.Approved
TolperisoneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tolperisone.Approved, Investigational
TopiramateThe risk or severity of adverse effects can be increased when Topiramate is combined with L-Tryptophan.Approved
TramadolThe risk or severity of serotonin syndrome can be increased when Tramadol is combined with L-Tryptophan.Approved, Investigational
TramiprosateThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tramiprosate.Investigational
TranylcypromineThe risk or severity of serotonin syndrome and hypomania can be increased when L-Tryptophan is combined with Tranylcypromine.Approved, Investigational
TrazodoneThe risk or severity of serotonin syndrome can be increased when Trazodone is combined with L-Tryptophan.Approved, Investigational
TriazolamThe risk or severity of adverse effects can be increased when Triazolam is combined with L-Tryptophan.Approved, Investigational
Tricaine methanesulfonateThe risk or severity of adverse effects can be increased when Tricaine methanesulfonate is combined with L-Tryptophan.Vet Approved
TrichloroethyleneThe risk or severity of adverse effects can be increased when Trichloroethylene is combined with L-Tryptophan.Approved
TriclofosThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Triclofos.Withdrawn
TrifluoperazineThe risk or severity of adverse effects can be increased when Trifluoperazine is combined with L-Tryptophan.Approved, Investigational
TrifluperidolThe risk or severity of adverse effects can be increased when Trifluperidol is combined with L-Tryptophan.Experimental
TriflupromazineThe risk or severity of adverse effects can be increased when Triflupromazine is combined with L-Tryptophan.Approved, Vet Approved
TrimethadioneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Trimethadione.Approved
TrimipramineThe risk or severity of serotonin syndrome can be increased when Trimipramine is combined with L-Tryptophan.Approved
TriprolidineThe risk or severity of adverse effects can be increased when Triprolidine is combined with L-Tryptophan.Approved
TropisetronThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tropisetron.Approved, Investigational
TubocurarineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Tubocurarine.Approved
UrapidilThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Urapidil.Investigational
VabicaserinThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Vabicaserin.Investigational
ValerianThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Valerian.Approved, Experimental, Investigational
ValnoctamideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Valnoctamide.Investigational
Valproate bismuthThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Valproate bismuth.Approved
Valproic AcidThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Valproic Acid.Approved, Investigational
ValpromideThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Valpromide.Experimental
VancomycinThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vancomycin.Approved
VecuroniumThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vecuronium.Approved
VenlafaxineThe risk or severity of serotonin syndrome can be increased when Venlafaxine is combined with L-Tryptophan.Approved
VeraliprideThe risk or severity of adverse effects can be increased when Veralipride is combined with L-Tryptophan.Experimental
VigabatrinThe risk or severity of adverse effects can be increased when Vigabatrin is combined with L-Tryptophan.Approved
VilazodoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Vilazodone.Approved
ViloxazineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Viloxazine.Approved, Investigational, Withdrawn
VinbarbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vinbarbital.Experimental
VinpocetineThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vinpocetine.Investigational
Vinyl etherThe risk or severity of adverse effects can be increased when Vinyl ether is combined with L-Tryptophan.Experimental
VinylbitalThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Vinylbital.Experimental
VortioxetineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Vortioxetine.Approved, Investigational
WortmanninThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Wortmannin.Experimental
XP19986The risk or severity of adverse effects can be increased when L-Tryptophan is combined with XP19986.Investigational
XylazineThe risk or severity of adverse effects can be increased when Xylazine is combined with L-Tryptophan.Vet Approved
YKP-1358The risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with YKP-1358.Investigational
YohimbineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Yohimbine.Approved, Investigational, Vet Approved
ZaleplonThe risk or severity of adverse effects can be increased when Zaleplon is combined with L-Tryptophan.Approved, Illicit, Investigational
ZiconotideThe risk or severity of adverse effects can be increased when Ziconotide is combined with L-Tryptophan.Approved
ZimelidineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Zimelidine.Withdrawn
ZiprasidoneThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Ziprasidone.Approved
ZolazepamThe risk or severity of adverse effects can be increased when Zolazepam is combined with L-Tryptophan.Vet Approved
ZolmitriptanThe risk or severity of serotonin syndrome can be increased when Zolmitriptan is combined with L-Tryptophan.Approved, Investigational
ZolpidemL-Tryptophan may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.Approved
ZonisamideThe risk or severity of adverse effects can be increased when Zonisamide is combined with L-Tryptophan.Approved, Investigational
ZopicloneThe risk or severity of adverse effects can be increased when L-Tryptophan is combined with Zopiclone.Approved
ZotepineThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Zotepine.Approved, Investigational, Withdrawn
ZuclopenthixolThe risk or severity of serotonin syndrome can be increased when L-Tryptophan is combined with Zuclopenthixol.Approved, Investigational
Food Interactions
Not Available

References

Synthesis Reference

Sten Vilhelm Gatenbeck, Per Olof Hedman, "Fermentative process for the production of L-tryptophan and its derivatives." U.S. Patent US3963572, issued April, 1974.

US3963572
General References
Not Available
External Links
Human Metabolome Database
HMDB0000929
KEGG Drug
D00020
KEGG Compound
C00078
PubChem Compound
6305
PubChem Substance
46508329
ChemSpider
6066
BindingDB
21974
ChEBI
16828
ChEMBL
CHEMBL54976
Therapeutic Targets Database
DAP001316
PharmGKB
PA10323
IUPHAR
717
Guide to Pharmacology
GtP Drug Page
HET
TRP
Wikipedia
Tryptophan
ATC Codes
N06AX02 — Tryptophan
AHFS Codes
  • 28:16.04 — Antidepressants
  • 28:16.04.92 — Miscellaneous Antidepressants
MSDS
Download (71.7 KB)

Clinical Trials

Clinical Trials
PhaseStatusPurposeConditionsCount
0RecruitingSupportive CareProtein Feeding in Post-traumatic Injury Patients1
2Active Not RecruitingTreatmentCarcinoid Tumors / Medulloblastomas / Neuroblastomas / Neuroendocrine Tumors1
2CompletedTreatmentCocaine-Related Disorders1
2, 3RecruitingTreatmentSchizophrenic Disorders1
3CompletedTreatmentCritical Illness1
3CompletedTreatmentInfant, Low Birth Weight / Infant, Small for Gestational Age / Infants, Premature / Newborn Infants / Sepsis1
3CompletedTreatmentParents2
4CompletedTreatmentAlzheimer's Disease (AD)1
4RecruitingSupportive CareMalnutrition1

Pharmacoeconomics

Manufacturers
Not Available
Packagers
  • Amend
  • B. Braun Melsungen AG
  • Mason Distributors
  • V Sab Medical Labs Inc.
Dosage forms
FormRouteStrength
Injection, solutionIntravenous
Injection, solution, concentrateIntravenous
LiquidHemodialysis
Injection, emulsionIntravenous
EmulsionIntravenous
LiquidIntravenous
CapsuleOral500 mg
TabletOral1 g
InjectionIntravenous
SolutionIntravenous
TabletOral250 mg
TabletOral500 mg
TabletOral750 mg
Prices
Unit descriptionCostUnit
Tryptan 1 g Tablet1.6USD tablet
Tryptan 750 mg Tablet1.2USD tablet
Apo-Tryptophan 1 g Tablet0.9USD tablet
Ratio-Tryptophan 1 g Tablet0.9USD tablet
Tryptan 500 mg Capsule0.8USD capsule
Tryptan 500 mg Tablet0.8USD tablet
L-tryptophan crystals0.72USD g
Apo-Tryptophan 500 mg Capsule0.45USD capsule
Apo-Tryptophan 500 mg Tablet0.45USD tablet
Pms-Tryptophan 500 mg Capsule0.45USD capsule
Pms-Tryptophan 500 mg Tablet0.45USD tablet
Ratio-Tryptophan 500 mg Capsule0.45USD capsule
Ratio-Tryptophan 500 mg Tablet0.45USD tablet
Tryptan 250 mg Tablet0.4USD tablet
L-tryptophan 500 mg capsule0.33USD capsule
DrugBank does not sell nor buy drugs. Pricing information is supplied for informational purposes only.
Patents
Not Available

Properties

State
Solid
Experimental Properties
PropertyValueSource
melting point (°C)290.5 dec °CPhysProp
water solubility1.34E+004 mg/L (at 25 °C)YALKOWSKY,SH & DANNENFELSER,RM (1992)
logP-1.06HANSCH,C ET AL. (1995)
logS-1.23ADME Research, USCD
pKa7.38 (at 25 °C)KORTUM,G ET AL (1961)
Predicted Properties
PropertyValueSource
Water Solubility1.36 mg/mLALOGPS
logP-1.1ALOGPS
logP-1.1ChemAxon
logS-2.2ALOGPS
pKa (Strongest Acidic)2.54ChemAxon
pKa (Strongest Basic)9.4ChemAxon
Physiological Charge0ChemAxon
Hydrogen Acceptor Count3ChemAxon
Hydrogen Donor Count3ChemAxon
Polar Surface Area79.11 Å2ChemAxon
Rotatable Bond Count3ChemAxon
Refractivity56.2 m3·mol-1ChemAxon
Polarizability21.05 Å3ChemAxon
Number of Rings2ChemAxon
Bioavailability1ChemAxon
Rule of FiveYesChemAxon
Ghose FilterNoChemAxon
Veber's RuleNoChemAxon
MDDR-like RuleNoChemAxon
Predicted ADMET features
PropertyValueProbability
Human Intestinal Absorption+0.984
Blood Brain Barrier+0.951
Caco-2 permeable-0.5943
P-glycoprotein substrateNon-substrate0.5988
P-glycoprotein inhibitor INon-inhibitor0.9951
P-glycoprotein inhibitor IINon-inhibitor0.9779
Renal organic cation transporterNon-inhibitor0.8805
CYP450 2C9 substrateNon-substrate0.8463
CYP450 2D6 substrateNon-substrate0.7897
CYP450 3A4 substrateNon-substrate0.7841
CYP450 1A2 substrateNon-inhibitor0.9531
CYP450 2C9 inhibitorNon-inhibitor0.9481
CYP450 2D6 inhibitorNon-inhibitor0.9307
CYP450 2C19 inhibitorNon-inhibitor0.9644
CYP450 3A4 inhibitorNon-inhibitor0.9432
CYP450 inhibitory promiscuityLow CYP Inhibitory Promiscuity0.9542
Ames testNon AMES toxic0.9284
CarcinogenicityNon-carcinogens0.931
BiodegradationNot ready biodegradable0.8348
Rat acute toxicity1.1785 LD50, mol/kg Not applicable
hERG inhibition (predictor I)Weak inhibitor0.9864
hERG inhibition (predictor II)Non-inhibitor0.9402
ADMET data is predicted using admetSAR, a free tool for evaluating chemical ADMET properties. (23092397)

Spectra

Mass Spec (NIST)
Download (7.51 KB)
Spectra
SpectrumSpectrum TypeSplash Key
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0udi-0190000000-feaec8547634dddcad8c
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0udi-0390000000-45a6c4fd79081597d44a
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies)GC-MSsplash10-0udi-0290000000-34f7274f31a4cb321a0b
GC-MS Spectrum - GC-EI-TOF (Pegasus III TOF-MS system, Leco; GC 6890, Agilent Technologies) (3 TMS)GC-MSsplash10-0fk9-9270000000-9761607cbe821f87f172
GC-MS Spectrum - GC-MS (1 TMS)GC-MSsplash10-001i-0900000000-3faeed7ad32e1755c03c
GC-MS Spectrum - GC-MS (3 TMS)GC-MSsplash10-0udi-0290000000-9c57a732e337fade3cb6
Predicted GC-MS Spectrum - GC-MSPredicted GC-MSNot Available
GC-MS Spectrum - EI-BGC-MSsplash10-001i-0900000000-d054a214c1717940989f
GC-MS Spectrum - EI-BGC-MSsplash10-0udi-0290000000-9860799c854e5c9ac1c7
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0udi-0190000000-feaec8547634dddcad8c
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0udi-0390000000-45a6c4fd79081597d44a
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0udi-0290000000-34f7274f31a4cb321a0b
GC-MS Spectrum - GC-EI-QQGC-MSsplash10-0udi-3729000000-86129db57aaf1a245f93
GC-MS Spectrum - GC-EI-TOFGC-MSsplash10-0fk9-9270000000-9761607cbe821f87f172
GC-MS Spectrum - GC-MSGC-MSsplash10-001i-0900000000-3faeed7ad32e1755c03c
GC-MS Spectrum - GC-MSGC-MSsplash10-0udi-0290000000-9c57a732e337fade3cb6
MS/MS Spectrum - Quattro_QQQ 10V, PositiveLC-MS/MSsplash10-000i-0910000000-db5439a5499b19881720
MS/MS Spectrum - Quattro_QQQ 25V, PositiveLC-MS/MSsplash10-014m-0900000000-cc4a579a29d19a1c0d44
MS/MS Spectrum - Quattro_QQQ 40V, PositiveLC-MS/MSsplash10-00kf-3900000000-a931a9df4c855603d06e
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0a4i-0290000000-5fa576241f151a3a01a2
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0002-0900000000-417ea0b6e4e18e5fbde1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-38f5ce97d594f3e3f12d
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-783ffff22f31096f238f
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0a4i-0290000000-3ced9d310dda312f8582
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-0002-0900000000-a050919a36b995d34553
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-1ddec73daead0ffadce4
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , PositiveLC-MS/MSsplash10-000i-0900000000-a8c9c60f075a675f6629
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0udi-0290602010-c09c931538bff74ac400
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0a4i-0900000000-0fed327c2a56f556e04c
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0udi-0090000000-98ec1c2c012e58eab924
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-00di-0090000000-fc77784da5d9b288d751
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0udi-0290601010-d6f94902c0cf639cb7bc
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0a4i-0900000000-27633a4f7ecfac45c730
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-0udi-0090000000-ee6cb8392b2e8d644bc1
LC-MS/MS Spectrum - LC-ESI-ITFT (LTQ Orbitrap XL, Thermo Scientfic) , NegativeLC-MS/MSsplash10-004i-0090000000-d81c86eceee1c9824b02
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, NegativeLC-MS/MSsplash10-0udi-0190000000-0e8b883dc8ab06c89d77
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, NegativeLC-MS/MSsplash10-0uxu-2940000000-cb35b9680612e19d8b3a
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, NegativeLC-MS/MSsplash10-014i-2900000000-7cc592351cc616b1d75f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, NegativeLC-MS/MSsplash10-014i-1900000000-987615a0add5eb2c3169
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, NegativeLC-MS/MSsplash10-014i-1900000000-f150d9d1e19c72d337a8
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 10V, PositiveLC-MS/MSsplash10-0a4r-0690000000-ea2d79df0b56be85abdd
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 20V, PositiveLC-MS/MSsplash10-000j-0900000000-585a12a5632c26e1132f
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 30V, PositiveLC-MS/MSsplash10-00kb-0900000000-6438d3945cf8a0273496
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 40V, PositiveLC-MS/MSsplash10-014i-0900000000-4dd8bf52e2f41311bcac
LC-MS/MS Spectrum - LC-ESI-QQ (API3000, Applied Biosystems) 50V, PositiveLC-MS/MSsplash10-014l-3900000000-145917d0d3838036008d
MS/MS Spectrum - CE-ESI-TOF (CE-system connected to 6210 Time-of-Flight MS, Agilent) , PositiveLC-MS/MSsplash10-0a4i-0090000000-ce0faa81be914aa3213a
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , PositiveLC-MS/MSsplash10-0a4i-0290000000-d610ff81bf083fe2f959
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) 30V, PositiveLC-MS/MSsplash10-0a4r-0980000000-4d3890c0f8cc3ff974ee
LC-MS/MS Spectrum - LC-ESI-QTOF (UPLC Q-Tof Premier, Waters) , NegativeLC-MS/MSsplash10-0uxr-2960000000-f4c878f3abb1609bb5c5
Predicted MS/MS Spectrum - 10V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Positive (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 10V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 20V, Negative (Annotated)Predicted LC-MS/MSNot Available
Predicted MS/MS Spectrum - 40V, Negative (Annotated)Predicted LC-MS/MSNot Available
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0udi-0090000000-c73c9b49139319c80b18
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0gb9-0930000000-da94834297fcc5b3d3c5
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-94061fd1f6b08445cdf3
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-e78172f4f27df232466e
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-014i-0900000000-93406e2cdb79770abc7d
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0udi-0190000000-0e8b883dc8ab06c89d77
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-0uxu-2940000000-cb35b9680612e19d8b3a
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-2900000000-5187dac98dbd6834d6ba
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-1900000000-987615a0add5eb2c3169
LC-MS/MS Spectrum - LC-ESI-QQ , negativeLC-MS/MSsplash10-014i-1900000000-174bb4d4390c75ae9a09
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-0fed327c2a56f556e04c
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-98ec1c2c012e58eab924
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-00di-0090000000-fc77784da5d9b288d751
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0a4i-0900000000-27633a4f7ecfac45c730
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-0udi-0090000000-ee6cb8392b2e8d644bc1
LC-MS/MS Spectrum - LC-ESI-ITFT , negativeLC-MS/MSsplash10-004i-0090000000-d81c86eceee1c9824b02
LC-MS/MS Spectrum - LC-ESI-QTOF , negativeLC-MS/MSsplash10-0uxr-2960000000-f4c878f3abb1609bb5c5
MS/MS Spectrum - Linear Ion Trap , negativeLC-MS/MSsplash10-0a4i-0900000000-03946c55ea12f371c0f4
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0910000000-b2a15c37af9ae0c2c71b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000b-0900000000-a7ab882061d0ea0246bd
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kg-0900000000-daa1ca87bd3e17326b4b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014l-0900000000-1427d47465a86f57a89c
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-014l-0900000000-3d0c62136805cda149ab
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-000i-0900000000-c85ba4facf645f32c4c7
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0002-0900000000-a765305b14a15909ae5b
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-00kg-0900000000-b1fdf0c754d5a54a9297
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-0a4r-0690000000-ea2d79df0b56be85abdd
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-000j-0900000000-585a12a5632c26e1132f
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-00kb-0900000000-6438d3945cf8a0273496
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014i-0900000000-4dd8bf52e2f41311bcac
LC-MS/MS Spectrum - LC-ESI-QQ , positiveLC-MS/MSsplash10-014l-3900000000-6f82948a09684218ff98
LC-MS/MS Spectrum - LC-ESI-IT , positiveLC-MS/MSsplash10-000i-0900000000-8043bd8b5eec986610ca
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-8feb1564836a7c8cf7c3
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-08ec725ead6beef6f58f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-cc72882cc54fd067136d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-5a28995ec71c65d15d95
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-417ea0b6e4e18e5fbde1
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-38f5ce97d594f3e3f12d
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-783ffff22f31096f238f
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-0002-0900000000-a050919a36b995d34553
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-1ddec73daead0ffadce4
LC-MS/MS Spectrum - LC-ESI-ITFT , positiveLC-MS/MSsplash10-000i-0900000000-a8c9c60f075a675f6629
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4i-0290000000-d610ff81bf083fe2f959
LC-MS/MS Spectrum - LC-ESI-QTOF , positiveLC-MS/MSsplash10-0a4r-0980000000-4d3890c0f8cc3ff974ee
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-000i-0900000000-8f9f550ed2290da4414b
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-03di-1190000000-1cdadf5d6ffa43da1f41
MS/MS Spectrum - Linear Ion Trap , positiveLC-MS/MSsplash10-0002-0920000000-07e999cba4b151f3150a
13C NMR Spectrum1D NMRNot Applicable
1H NMR Spectrum1D NMRNot Applicable
[1H,1H] 2D NMR Spectrum2D NMRNot Applicable
[1H,13C] 2D NMR Spectrum2D NMRNot Applicable

Taxonomy

Description
This compound belongs to the class of organic compounds known as indolyl carboxylic acids and derivatives. These are compounds containing a carboxylic acid chain (of at least 2 carbon atoms) linked to an indole ring.
Kingdom
Organic compounds
Super Class
Organoheterocyclic compounds
Class
Indoles and derivatives
Sub Class
Indolyl carboxylic acids and derivatives
Direct Parent
Indolyl carboxylic acids and derivatives
Alternative Parents
L-alpha-amino acids / 3-alkylindoles / Aralkylamines / Substituted pyrroles / Benzenoids / Heteroaromatic compounds / Amino acids / Monocarboxylic acids and derivatives / Carboxylic acids / Azacyclic compounds
show 5 more
Substituents
Indolyl carboxylic acid derivative / Alpha-amino acid / Alpha-amino acid or derivatives / L-alpha-amino acid / 3-alkylindole / Indole / Aralkylamine / Benzenoid / Substituted pyrrole / Heteroaromatic compound
show 19 more
Molecular Framework
Aromatic heteropolycyclic compounds
External Descriptors
proteinogenic amino acid, L-alpha-amino acid, tryptophan, erythrose 4-phosphate/phosphoenolpyruvate family amino acid (CHEBI:16828) / Common amino acids (C00078)

Targets

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Not Available
Gene Name
WARS2
Uniprot ID
Q9UGM6
Uniprot Name
Tryptophan--tRNA ligase, mitochondrial
Molecular Weight
40146.265 Da
References
  1. Paley EL, Denisova G, Sokolova O, Posternak N, Wang X, Brownell AL: Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models. Neuromolecular Med. 2007;9(1):55-82. [PubMed:17114825]
  2. Retailleau P, Weinreb V, Hu M, Carter CW Jr: Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28. Epub 2007 Mar 12. [PubMed:17428498]
  3. Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M: T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006 May;47(5):2125-34. [PubMed:16639024]
  4. Yang XL, Otero FJ, Ewalt KL, Liu J, Swairjo MA, Kohrer C, RajBhandary UL, Skene RJ, McRee DE, Schimmel P: Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J. 2006 Jun 21;25(12):2919-29. Epub 2006 May 25. [PubMed:16724112]
  5. Charriere F, Helgadottir S, Horn EK, Soll D, Schneider A: Dual targeting of a single tRNA(Trp) requires two different tryptophanyl-tRNA synthetases in Trypanosoma brucei. Proc Natl Acad Sci U S A. 2006 May 2;103(18):6847-52. Epub 2006 Apr 24. [PubMed:16636268]
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Not Available
Gene Name
trpS
Uniprot ID
P00953
Uniprot Name
Tryptophan--tRNA ligase
Molecular Weight
37192.385 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tsuchiya W, Umehara T, Kuno A, Hasegawa T: Determination of tryptophan tRNA recognition sites for tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1. Nucleic Acids Symp Ser (Oxf). 2004;(48):185-6. [PubMed:17150540]
  4. Kovaleva GK, Favorova OO, Moroz SG, Krauspe R, Kiselev LL: [Active intermediate compound of tryptophanyl-tRNA-synthetase with tryptophan]. Dokl Akad Nauk SSSR. 1976;229(2):492-5. [PubMed:971661]
  5. Kovaleva GK, Degtiarev SKh, Favorova OO: [Affinity modification of tryptophanyl-tRNA synthetase by an alkylating L-tryptophan analog]. Mol Biol (Mosk). 1979 Nov-Dec;13(6):1237-46. [PubMed:547176]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Isoform 1, isoform 2 and T1-TrpRS have aminoacylation activity while T2-TrpRS lacks it. Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. T2-TrpRS inhibits f...
Gene Name
WARS
Uniprot ID
P23381
Uniprot Name
Tryptophan--tRNA ligase, cytoplasmic
Molecular Weight
53164.91 Da
References
  1. Tsuchiya W, Umehara T, Kuno A, Hasegawa T: Determination of tryptophan tRNA recognition sites for tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1. Nucleic Acids Symp Ser (Oxf). 2004;(48):185-6. [PubMed:17150540]
  2. Retailleau P, Weinreb V, Hu M, Carter CW Jr: Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28. Epub 2007 Mar 12. [PubMed:17428498]
  3. Zhu L, Ji F, Wang Y, Zhang Y, Liu Q, Zhang JZ, Matsushima K, Cao Q, Zhang Y: Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol. 2006 Dec 1;177(11):8226-33. [PubMed:17114500]
  4. Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, Lanigan CM, Fox HS: IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007 Oct;55(13):1385-96. [PubMed:17661345]
  5. Yang XL, Otero FJ, Ewalt KL, Liu J, Swairjo MA, Kohrer C, RajBhandary UL, Skene RJ, McRee DE, Schimmel P: Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J. 2006 Jun 21;25(12):2919-29. Epub 2006 May 25. [PubMed:16724112]

Enzymes

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Tryptophan 2,3-dioxygenase activity
Specific Function
Incorporates oxygen into the indole moiety of tryptophan. Has a broad specificity towards tryptamine and derivatives including D- and L-tryptophan, 5-hydroxytryptophan and serotonin (By similarity).
Gene Name
TDO2
Uniprot ID
P48775
Uniprot Name
Tryptophan 2,3-dioxygenase
Molecular Weight
47871.215 Da
References
  1. Rafice SA, Chauhan N, Efimov I, Basran J, Raven EL: Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem Soc Trans. 2009 Apr;37(Pt 2):408-12. doi: 10.1042/BST0370408. [PubMed:19290871]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Pyridoxal phosphate binding
Specific Function
Catalyzes the decarboxylation of L-3,4-dihydroxyphenylalanine (DOPA) to dopamine, L-5-hydroxytryptophan to serotonin and L-tryptophan to tryptamine.
Gene Name
DDC
Uniprot ID
P20711
Uniprot Name
Aromatic-L-amino-acid decarboxylase
Molecular Weight
53925.815 Da
References
  1. Tyce GM: Origin and metabolism of serotonin. J Cardiovasc Pharmacol. 1990;16 Suppl 3:S1-7. [PubMed:1369709]
Kind
Protein
Organism
Geobacillus stearothermophilus
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Not Available
Gene Name
trpS
Uniprot ID
P00953
Uniprot Name
Tryptophan--tRNA ligase
Molecular Weight
37192.385 Da
References
  1. Overington JP, Al-Lazikani B, Hopkins AL: How many drug targets are there? Nat Rev Drug Discov. 2006 Dec;5(12):993-6. [PubMed:17139284]
  2. Imming P, Sinning C, Meyer A: Drugs, their targets and the nature and number of drug targets. Nat Rev Drug Discov. 2006 Oct;5(10):821-34. [PubMed:17016423]
  3. Tsuchiya W, Umehara T, Kuno A, Hasegawa T: Determination of tryptophan tRNA recognition sites for tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1. Nucleic Acids Symp Ser (Oxf). 2004;(48):185-6. [PubMed:17150540]
  4. Kovaleva GK, Favorova OO, Moroz SG, Krauspe R, Kiselev LL: [Active intermediate compound of tryptophanyl-tRNA-synthetase with tryptophan]. Dokl Akad Nauk SSSR. 1976;229(2):492-5. [PubMed:971661]
  5. Kovaleva GK, Degtiarev SKh, Favorova OO: [Affinity modification of tryptophanyl-tRNA synthetase by an alkylating L-tryptophan analog]. Mol Biol (Mosk). 1979 Nov-Dec;13(6):1237-46. [PubMed:547176]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Not Available
Gene Name
WARS2
Uniprot ID
Q9UGM6
Uniprot Name
Tryptophan--tRNA ligase, mitochondrial
Molecular Weight
40146.265 Da
References
  1. Paley EL, Denisova G, Sokolova O, Posternak N, Wang X, Brownell AL: Tryptamine induces tryptophanyl-tRNA synthetase-mediated neurodegeneration with neurofibrillary tangles in human cell and mouse models. Neuromolecular Med. 2007;9(1):55-82. [PubMed:17114825]
  2. Retailleau P, Weinreb V, Hu M, Carter CW Jr: Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28. Epub 2007 Mar 12. [PubMed:17428498]
  3. Banin E, Dorrell MI, Aguilar E, Ritter MR, Aderman CM, Smith AC, Friedlander J, Friedlander M: T2-TrpRS inhibits preretinal neovascularization and enhances physiological vascular regrowth in OIR as assessed by a new method of quantification. Invest Ophthalmol Vis Sci. 2006 May;47(5):2125-34. [PubMed:16639024]
  4. Yang XL, Otero FJ, Ewalt KL, Liu J, Swairjo MA, Kohrer C, RajBhandary UL, Skene RJ, McRee DE, Schimmel P: Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J. 2006 Jun 21;25(12):2919-29. Epub 2006 May 25. [PubMed:16724112]
  5. Charriere F, Helgadottir S, Horn EK, Soll D, Schneider A: Dual targeting of a single tRNA(Trp) requires two different tryptophanyl-tRNA synthetases in Trypanosoma brucei. Proc Natl Acad Sci U S A. 2006 May 2;103(18):6847-52. Epub 2006 Apr 24. [PubMed:16636268]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Tryptophan 5-monooxygenase activity
Specific Function
Not Available
Gene Name
TPH1
Uniprot ID
P17752
Uniprot Name
Tryptophan 5-hydroxylase 1
Molecular Weight
50984.725 Da
References
  1. Pavon JA, Fitzpatrick PF: Insights into the catalytic mechanisms of phenylalanine and tryptophan hydroxylase from kinetic isotope effects on aromatic hydroxylation. Biochemistry. 2006 Sep 12;45(36):11030-7. [PubMed:16953590]
  2. Langfort J, Baranczuk E, Pawlak D, Chalimoniuk M, Lukacova N, Marsala J, Gorski J: The effect of endurance training on regional serotonin metabolism in the brain during early stage of detraining period in the female rat. Cell Mol Neurobiol. 2006 Oct-Nov;26(7-8):1327-42. Epub 2006 Aug 1. [PubMed:16897368]
  3. Nakamura K, Hasegawa H: Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol. 2007 Feb;35(1):45-54. [PubMed:17519505]
  4. Invernizzi RW: Role of TPH-2 in brain function: news from behavioral and pharmacologic studies. J Neurosci Res. 2007 Nov 1;85(14):3030-5. [PubMed:17492791]
  5. Neckameyer WS, Coleman CM, Eadie S, Goodwin SF: Compartmentalization of neuronal and peripheral serotonin synthesis in Drosophila melanogaster. Genes Brain Behav. 2007 Nov;6(8):756-69. Epub 2007 Mar 21. [PubMed:17376153]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Tryptophan 5-monooxygenase activity
Specific Function
Not Available
Gene Name
TPH2
Uniprot ID
Q8IWU9
Uniprot Name
Tryptophan 5-hydroxylase 2
Molecular Weight
56056.295 Da
References
  1. Lopez VA, Detera-Wadleigh S, Cardona I, Kassem L, McMahon FJ: Nested association between genetic variation in tryptophan hydroxylase II, bipolar affective disorder, and suicide attempts. Biol Psychiatry. 2007 Jan 15;61(2):181-6. Epub 2006 Jun 27. [PubMed:16806105]
  2. Kraus MR, Al-Taie O, Schafer A, Pfersdorff M, Lesch KP, Scheurlen M: Serotonin-1A receptor gene HTR1A variation predicts interferon-induced depression in chronic hepatitis C. Gastroenterology. 2007 Apr;132(4):1279-86. Epub 2007 Feb 25. [PubMed:17408646]
  3. Nakamura K, Hasegawa H: Developmental role of tryptophan hydroxylase in the nervous system. Mol Neurobiol. 2007 Feb;35(1):45-54. [PubMed:17519505]
  4. Invernizzi RW: Role of TPH-2 in brain function: news from behavioral and pharmacologic studies. J Neurosci Res. 2007 Nov 1;85(14):3030-5. [PubMed:17492791]
  5. Calcagno E, Canetta A, Guzzetti S, Cervo L, Invernizzi RW: Strain differences in basal and post-citalopram extracellular 5-HT in the mouse medial prefrontal cortex and dorsal hippocampus: relation with tryptophan hydroxylase-2 activity. J Neurochem. 2007 Nov;103(3):1111-20. Epub 2007 Jul 31. [PubMed:17666043]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
Inhibitor
General Function
Tryptophan-trna ligase activity
Specific Function
Isoform 1, isoform 2 and T1-TrpRS have aminoacylation activity while T2-TrpRS lacks it. Isoform 2, T1-TrpRS and T2-TrpRS possess angiostatic activity whereas isoform 1 lacks it. T2-TrpRS inhibits f...
Gene Name
WARS
Uniprot ID
P23381
Uniprot Name
Tryptophan--tRNA ligase, cytoplasmic
Molecular Weight
53164.91 Da
References
  1. Tsuchiya W, Umehara T, Kuno A, Hasegawa T: Determination of tryptophan tRNA recognition sites for tryptophanyl-tRNA synthetase from hyperthermophilic archaeon, Aeropyrum pernix K1. Nucleic Acids Symp Ser (Oxf). 2004;(48):185-6. [PubMed:17150540]
  2. Retailleau P, Weinreb V, Hu M, Carter CW Jr: Crystal structure of tryptophanyl-tRNA synthetase complexed with adenosine-5' tetraphosphate: evidence for distributed use of catalytic binding energy in amino acid activation by class I aminoacyl-tRNA synthetases. J Mol Biol. 2007 May 25;369(1):108-28. Epub 2007 Mar 12. [PubMed:17428498]
  3. Zhu L, Ji F, Wang Y, Zhang Y, Liu Q, Zhang JZ, Matsushima K, Cao Q, Zhang Y: Synovial autoreactive T cells in rheumatoid arthritis resist IDO-mediated inhibition. J Immunol. 2006 Dec 1;177(11):8226-33. [PubMed:17114500]
  4. Yadav MC, Burudi EM, Alirezaei M, Flynn CC, Watry DD, Lanigan CM, Fox HS: IFN-gamma-induced IDO and WRS expression in microglia is differentially regulated by IL-4. Glia. 2007 Oct;55(13):1385-96. [PubMed:17661345]
  5. Yang XL, Otero FJ, Ewalt KL, Liu J, Swairjo MA, Kohrer C, RajBhandary UL, Skene RJ, McRee DE, Schimmel P: Two conformations of a crystalline human tRNA synthetase-tRNA complex: implications for protein synthesis. EMBO J. 2006 Jun 21;25(12):2919-29. Epub 2006 May 25. [PubMed:16724112]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Substrate
General Function
Tryptophan 2,3-dioxygenase activity
Specific Function
Catalyzes the first and rate limiting step of the catabolism of the essential amino acid tryptophan along the kynurenine pathway (PubMed:17671174). Involved in the peripheral immune tolerance, cont...
Gene Name
IDO1
Uniprot ID
P14902
Uniprot Name
Indoleamine 2,3-dioxygenase 1
Molecular Weight
45325.89 Da
References
  1. Agaugue S, Perrin-Cocon L, Coutant F, Andre P, Lotteau V: 1-Methyl-tryptophan can interfere with TLR signaling in dendritic cells independently of IDO activity. J Immunol. 2006 Aug 15;177(4):2061-71. [PubMed:16887964]
  2. Fallarino F, Gizzi S, Mosci P, Grohmann U, Puccetti P: Tryptophan catabolism in IDO+ plasmacytoid dendritic cells. Curr Drug Metab. 2007 Apr;8(3):209-16. [PubMed:17430109]
  3. Cozzi A, Zignego AL, Carpendo R, Biagiotti T, Aldinucci A, Monti M, Giannini C, Rosselli M, Laffi G, Moroni F: Low serum tryptophan levels, reduced macrophage IDO activity and high frequency of psychopathology in HCV patients. J Viral Hepat. 2006 Jun;13(6):402-8. [PubMed:16842443]
  4. Grohmann U, Volpi C, Fallarino F, Bozza S, Bianchi R, Vacca C, Orabona C, Belladonna ML, Ayroldi E, Nocentini G, Boon L, Bistoni F, Fioretti MC, Romani L, Riccardi C, Puccetti P: Reverse signaling through GITR ligand enables dexamethasone to activate IDO in allergy. Nat Med. 2007 May;13(5):579-86. Epub 2007 Apr 8. [PubMed:17417651]
  5. Zheng X, Koropatnick J, Li M, Zhang X, Ling F, Ren X, Hao X, Sun H, Vladau C, Franek JA, Feng B, Urquhart BL, Zhong R, Freeman DJ, Garcia B, Min WP: Reinstalling antitumor immunity by inhibiting tumor-derived immunosuppressive molecule IDO through RNA interference. J Immunol. 2006 Oct 15;177(8):5639-46. [PubMed:17015752]
  6. Chen X, Ji ZL, Chen YZ: TTD: Therapeutic Target Database. Nucleic Acids Res. 2002 Jan 1;30(1):412-5. [PubMed:11752352]
  7. Rafice SA, Chauhan N, Efimov I, Basran J, Raven EL: Oxidation of L-tryptophan in biology: a comparison between tryptophan 2,3-dioxygenase and indoleamine 2,3-dioxygenase. Biochem Soc Trans. 2009 Apr;37(Pt 2):408-12. doi: 10.1042/BST0370408. [PubMed:19290871]

Transporters

Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Very active and specific thyroid hormone transporter. Stimulates cellular uptake of thyroxine (T4), triiodothyronine (T3), reverse triiodothyronine (rT3) and diidothyronine. Does not transport Leu,...
Gene Name
SLC16A2
Uniprot ID
P36021
Uniprot Name
Monocarboxylate transporter 8
Molecular Weight
59510.86 Da
References
  1. Friesema EC, Ganguly S, Abdalla A, Manning Fox JE, Halestrap AP, Visser TJ: Identification of monocarboxylate transporter 8 as a specific thyroid hormone transporter. J Biol Chem. 2003 Oct 10;278(41):40128-35. Epub 2003 Jul 18. [PubMed:12871948]
Kind
Protein
Organism
Human
Pharmacological action
Unknown
Actions
Inhibitor
General Function
Transporter activity
Specific Function
Sodium-independent transporter that mediates the update of aromatic acid. Can function as a net efflux pathway for aromatic amino acids in the basosolateral epithelial cells (By similarity).
Gene Name
SLC16A10
Uniprot ID
Q8TF71
Uniprot Name
Monocarboxylate transporter 10
Molecular Weight
55492.07 Da
References
  1. Kim DK, Kanai Y, Matsuo H, Kim JY, Chairoungdua A, Kobayashi Y, Enomoto A, Cha SH, Goya T, Endou H: The human T-type amino acid transporter-1: characterization, gene organization, and chromosomal location. Genomics. 2002 Jan;79(1):95-103. [PubMed:11827462]
  2. Kim DK, Kanai Y, Chairoungdua A, Matsuo H, Cha SH, Endou H: Expression cloning of a Na+-independent aromatic amino acid transporter with structural similarity to H+/monocarboxylate transporters. J Biol Chem. 2001 May 18;276(20):17221-8. Epub 2001 Feb 20. [PubMed:11278508]

Drug created on June 13, 2005 07:24 / Updated on September 17, 2018 20:35